Health benefits attributed to 17α-estradiol, a lifespan-extending compound, are mediated through estrogen receptor α

Shivani N Mann1,2,3, Niran Hadad4, Molly Nelson Holte5, Alicia R Rothman1, Roshini Sathiaseelan1, Samim Ali Mondal1, Martin-Paul Agbaga3,6,7, Archana Unnikrishnan3,8, Malayannan Subramaniam5, John Hawse5, Derek M Huffman9, Willard M Freeman2,10,11, Michael B Stout1,2,3*

1Department of Nutritional Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, United States; 2Oklahoma Center for Geroscience, University of Oklahoma Health Sciences Center, Oklahoma City, United States; 3Harold Hamm Diabetes Center, University of Oklahoma Health Sciences Center, Oklahoma City, United States; 4The Jackson Laboratory, Bar Harbor, United States; 5Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, United States; 6Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, United States; 7Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, United States; 8Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, United States; 9Department of Molecular Pharmacology, Albert Einstein College of Medicine, New York, United States; 10Genes & Human Disease Research Program, Oklahoma Medical Research Foundation, Oklahoma City, United States; 11Oklahoma City Veterans Affairs Medical Center, Oklahoma City, United States

Abstract Metabolic dysfunction underlies several chronic diseases, many of which are exacerbated by obesity. Dietary interventions can reverse metabolic declines and slow aging, although compliance issues remain paramount. 17α-estradiol treatment improves metabolic parameters and slows aging in male mice. The mechanisms by which 17α-estradiol elicits these benefits remain unresolved. Herein, we show that 17α-estradiol elicits similar genomic binding and transcriptional activation through estrogen receptor α (ERα) to that of 17β-estradiol. In addition, we show that the ablation of ERα completely attenuates the beneficial metabolic effects of 17α-E2 in male mice. Our findings suggest that 17α-E2 may act through the liver and hypothalamus to improve metabolic parameters in male mice. Lastly, we also determined that 17α-E2 improves metabolic parameters in male rats, thereby proving that the beneficial effects of 17α-E2 are not limited to mice. Collectively, these studies suggest ERα may be a drug target for mitigating chronic diseases in male mammals.

Introduction Aging is the leading risk factor for most chronic diseases, many of which are associated with declines in metabolic homeostasis (López-Otín et al., 2013). Metabolic detriments associated with advancing age are further exacerbated by obesity (Villareal et al., 2005; Waters et al., 2013), which has risen...
substantially in the older population (>65 years) over the past several decades (Flegal et al., 2010; Flegal et al., 2016). Moreover, obesity in mid-life has been shown to accelerate aging mechanisms and induce phenotypes more commonly observed in older mammals (Bischof and Park, 2015; Horvath et al., 2014; Nevalainen et al., 2017; Yang et al., 2009; Whitmer et al., 2005a; Whitmer et al., 2005b; Dye et al., 2017). These observations have led many to postulate that obesity may represent a mild progeria syndrome (Salvestrini et al., 2019; Tzanetakou et al., 2012; Pérez et al., 2016; Tchkonia et al., 2010; Stout et al., 2017a).

Although it is well established that dietary interventions, including calorie restriction, can reverse obesity-related metabolic sequelae, many of these strategies are not well tolerated in older patients due to concomitant comorbidities (Villareal et al., 2005; Jensen et al., 2014). Compliance issues across all age groups also remain a paramount hurdle due to calorie restriction adversely affecting mood, thermoregulation, and musculoskeletal mass (Dirks and Leeuwenburgh, 2006). These adverse health outcomes demonstrate the need for pharmacological approaches aimed at curtailing metabolic perturbations associated with obesity and aging.

17α-estradiol (17α-E2) is one of the more recently studied compounds to demonstrate efficacy for beneficially modulating obesity- and age-related health outcomes. The NIA Interventions Testing Program (ITP) found that long-term administration of 17α-E2 extends median lifespan of male mice in a dose-dependent manner (Strong et al., 2016; Harrison et al., 2014). Our group has been exploring potential mechanisms by which 17α-E2 may improve healthspan and extend lifespan in a sex-specific manner. We have found that 17α-E2 administration reduces calorie intake and regional adiposity in combination with significant improvements in a multitude of systemic metabolic parameters in both middle-aged obese and old male mice without inducing deleterious effects (Stout et al., 2017b; Steyn et al., 2018; Miller, 2020). Other groups have also determined that lifelong administration of 17α-E2 beneficially modulates metabolic outcomes, including glucose tolerance, mTORC2 signaling, and hepatic amino acid composition and markers of urea cycling, which were reported to be dependent upon the presence of endogenous androgens (Garratt et al., 2017; Garratt et al., 2018). Additionally, multiple lifespan extending compounds, including 17α-E2, exhibit similar modifications in liver function (Tyshkovskiy et al., 2019). In all, recent studies by several independent laboratories strongly indicate that the lifespan-extending effects of 17α-E2 are at least associated with, if not dependent on, metabolic improvements.

Despite the mounting evidence demonstrating that 17α-E2 improves numerous health parameters, the signaling mechanism(s) and primary tissues through which 17α-E2 elicits these benefits remain unknown. Although 17α-E2 is a naturally occurring enantiomer to 17β-estradiol (17β-E2), it has been postulated that 17α-E2 signals through a novel uncharacterized receptor (Toran-Allerand, 2005; Toran-Allerand et al., 2002; Toran-Allerand et al., 2005; Green and Simpkins, 2000) as opposed to classical estrogen receptors α (ERα) and β (ERβ), which is due to 17α-E2 having significantly reduced binding affinity for ERα and ERβ as compared to 17β-E2 (Edwards and McGuire, 1980; Korenman, 1969; Littlefield et al., 1990; Anstead et al., 1997). For this reason, 17α-E2 is often referred to as a non-feminizing estrogen (Green and Simpkins, 2000; Engler-Chiurazzi et al., 2017; Kaur et al., 2015). A few studies have suggested that a novel but uncharacterized estrogen receptor, termed ER-X, may mediate 17α-E2 actions in the brain (Toran-Allerand, 2005; Toran-Allerand et al., 2002; Toran-Allerand et al., 2005; Green and Simpkins, 2000), although more recent studies supporting this hypothesis are lacking in the literature. Similarly, no reports to date have directly tested whether the doses of 17α-E2 shown to improve healthspan and lifespan in mice are mediated through ERα and/or ERβ.

There is a multitude of data in the diabetes and metabolism literature demonstrating that ERα is a regulator of systemic metabolic parameters. Although most of these studies have historically been performed in female mammals, more recent studies have demonstrated that ERα also plays a critical role in modulating metabolism in male mammals. For instance, Allard and colleagues recently demonstrated that genomic actions of ERα regulate systemic glucose homeostasis in mice of both sexes and insulin production and release in males (Allard et al., 2019). Other studies have also determined that hepatic steatosis and insulin sensitivity, and therefore the control of gluconeogenesis, are regulated through FOXO1 in an ERα-dependent manner in male mice (Yan et al., 2019). Furthermore, hepatocyte-specific deletion of ERα was sufficient to abrogate similar estrogen-mediated metabolic benefits (Guillaume et al., 2019; Qiu et al., 2017; Meda et al., 2020). Given that several reports have linked the administration of 17α-E2 to improvements in metabolic homeostasis, we...
hypothesized that 17α-E2 signals through ERα to modulate hepatic function and systemic metabolism, thereby potentially contributing to the lifespan-extending effects of 17α-E2.

The work outlined in this report sought to determine if ERα is the primary receptor by 17α-E2 signals and modulates health parameters in mice. We initially determined that 17α-E2 and 17β-E2 elicit similar genomic actions through ERα. Given that no studies to date have tested the potential role of ERα in modulating 17α-E2-mediated effects in vivo, we treated obese wild type (WT) and ERα knockout (ERα KO) littermate mice with 17α-E2 to determine if the ablation of ERα could attenuate 17α-E2-induced benefits on adiposity, metabolic homeostasis, and hepatic function. We found that the ablation of ERα completely attenuated all beneficial metabolic effects of 17α-E2. Follow-up studies in male WT rats undergoing hyperinsulinemic-euglycemic clamps revealed that 17α-E2 modulates hepatic insulin sensitivity following acute exposure. Given the established connection between the hypothalamus and liver in the modulation of hepatic insulin sensitivity (Könnner et al., 2007; Ruud et al., 2017; Pocai et al., 2005a; Pocai et al., 2005b; Dodd et al., 2018), coupled with our data demonstrating ERα-dependency of 17α-E2 actions on metabolic parameters, we speculate that 17α-E2 acts through ERα in the liver and/or hypothalamus to improve metabolic homeostasis in male mammals.

Results

17α-E2 and 17β-E2 similarly modulate genomic binding and transcriptional activity of ERα

Ligand-mediated ERα dimerization leads to nuclear translocation and transcriptional activity. Previous work has shown that 17α-E2 and 17β-E2 can bind to ERα with different affinities (Edwards and McGuire, 1980; Korenman, 1969; Littlefield et al., 1990; Anstead et al., 1997), yet potential differences in resultant genomic binding and transcriptional activity between the two ligands remains unexplored. We assessed ERα DNA binding and transcriptional induction following exposure to 17β-E2 (10 nM) or 17α-E2 (10 nM or 100 nM) in U2OS cells that stably express ERα following doxycycline induction. We chose to use these cells because they do not endogenously express any form of ERα or ERβ and have been extensively utilized to elucidate the effects of ERα and ERβ agonists and antagonists on gene expression (Monroe et al., 2003; Monroe et al., 2005). ChIP-sequencing revealed peaks of ERα genomic binding in all conditions, that when compared, are qualitatively similar across treatments (Figure 1A). Statistically significant differences in ERα binding were determined by negative binomial regression with a Wald’s pairwise post-hoc comparison (false discovery rate correction, FDR < 0.05). A total of 21,443 peaks were found to have a significant pairwise post-hoc comparison between vehicle and 17α-E2 and/or 17β-E2 treated cells. No statistically significant differences between 17α-E2 and 17β-E2-treated groups were observed. 17α-E2 and 17β-E2 not only induced ERα binding at the same genomic locations but also to similar magnitudes. Comparing the levels of increased or decreased ERα binding (as compared to vehicle control) between treatments demonstrates the consistency of ERα genomic binding regardless of the agonist (Figure 1B, Supplementary file 1). The degree of increased or decreased ERα binding was highly similar between 10 nM 17α-E2 and 10 nM 17β-E2, (Pearson’s r = 0.95, p<0.001) and 100 nM 17α-E2 and 10 nM 17β-E2 (Pearson’s r = 0.96, p<0.001). As expected, ERα-binding sites were enriched for estrogen response elements (ERE), estrogen-related receptor beta (Esrrb), and estrogen-related receptor alpha (Errα). Other common motifs found within ER elements, including steroidogenic factor-1 (SF1) (Lin et al., 2007), and motif elements of known interacting partners, including retinoid acid receptor:retinoid X receptor (RAR:RXR) (Lee et al., 1998), were also enriched (Figure 1C). In addition, we observed enrichment of androgen response elements (ARE) in ERα peaks (Figure 1C). Of particular relevance, many of the top enriched motifs identified contained the ERE consensus sequence TTGAC (Supplementary file 2). Following motif enrichment, we performed pairwise differential motif enrichment across all groups to determine if a specific agonist or agonist concentration caused a differential enrichment of any motifs, as would be suggestive of differential genomic binding. No differential motif binding was observed across treatment groups indicating that both 17α-E2 and 17β-E2 cause ERα to bind to the same types of genomic elements (Hypergeometric test, FDR < 0.05).
**Figure 1.** 17α-E2 and 17β-E2 elicit similar genomic binding and transcriptional profiles through ERα. (A) Heatmap representing normalized genome-wide DNA binding by ERα via ChIP sequencing analyses centered according to peak summits for each treatment group and compared to each other group. (B) Differential binding was identified between vehicle and 17α-E2 or 17β-E2 treatment groups, but no differences were identified between 17α-E2 and 17β-E2-treated groups (negative binomial regression, followed by Wald test for pairwise comparisons, FDR < 0.05). Fold change in binding relative to vehicle control was compared between 17α-E2 treatments and 17β-E2. (C) Motif enrichment analysis, filtered for mammalian and non-overlapping motif groups, showing the top 10 non-redundant enriched sequence motifs across treatment groups (hypergeometric test, FDR < 0.05). (D) PCA plot of transcriptional profiles by RNA sequencing analyses demonstrating clustering of 17α-E2 and 17β-E2 treatment groups together, opposite from Vehicle-treated group along the first principle component, and (E) Heatmap representing differentially expressed genes (negative binomial regression, followed by Wald test for pairwise comparisons, FDR < 0.05) by RNA sequencing analyses (left) and ERα binding patterns within the gene body ±5 kb flanking regions of these genes via ChIP sequencing (right). Significant differential pairwise expression was observed only between 17α-E2 and 17β-E2 treatment groups and vehicle-treated control. These studies utilized U2OS-ERα cells treated with low dose (10 nM) 17α-E2, high dose (100 nM) 17α-E2, 17β-E2 (10 nM), or vehicle (EtOH). n = 3/group.

*Figure 1 continued on next page*
The online version of this article includes the following figure supplement(s) for figure 1:

**Figure supplement 1.** 17α-E2 and 17β-E2 elicit similar ERα binding profile.

Next, we examined potential differences in transcriptional responses between treatment groups using RNA-sequencing. Principle component analysis based on the entire transcriptome revealed that all samples exposed to either 17α-E2 or 17β-E2 clustered together, whereas vehicle-treated cells remained distinctly separated from treated cells on the first principle component, which explains the majority of the variance in transcription (70.6%) (Figure 1D). These data suggest that treatment vs vehicle is the primary covariate explaining variance in transcriptional profiles, not the specific agonist. Next, differential expression was assessed between all groups using a negative binomial regression model with a Wald pairwise post-hoc test. No genes were found to be differentially regulated (FDR < 0.05) between the estrogen treatments. Yet, compared to vehicle-treated cells, treatment of U2OS cells with either 10 nM or 100 nM 17α-E2 or 10 nM 17β-E2 resulted in nearly identical gene suppression and activation signatures (Figure 1E, left). Additionally, both 17α-E2 or 17β-E2 treatment conditions resulted in higher ERα DNA binding affinity to gene bodies of these differentially expressed transcripts compared to vehicle treatment, and no differences were observed between 17α-E2 and 17β-E2 conditions (Figure 1E, right) (negative binomial regression with Wald pairwise post-hoc). These findings led us to postulate that 17α-E2 may be the signaling through ERα to modulate health parameters in male mice. As such, we subsequently sought to determine if the ablation of ERα in vivo would mitigate the effects of 17α-E2.

**ERα ablation attenuates 17α-E2-mediated benefits on metabolic parameters in male mice in vivo**

To induce obesity and metabolic perturbations in male mice, we administered high-fat diet (HFD) for several months prior to initiating 17α-E2 treatment. Control mice remained on HFD, whereas 17α-E2-treated mice were switched to an identical HFD containing 17α-E2. Almost immediately after 17α-E2 treatment began, male WT mice displayed significant reductions in mass (Figure 2A–B) and adiposity (Figure 2C–D). This is aligned with our previous reports demonstrating that 17α-E2 administration quickly reduces body mass and adiposity (Stout et al., 2017b; Steyn et al., 2018; Miller, 2020), which we have linked to hypothalamic regulation of anorexigenic signaling pathways (Steyn et al., 2018). Indeed, male WT mice in the current study also displayed robust declines in calorie consumption during the first 4 weeks of treatment (Figure 2E). Conversely, all these benefits were completely abolished in male mice lacking ERα (ERα KO), thereby confirming that 17α-E2 definitively acts through ERα to modulate feeding behaviors, mass, and adiposity in male mice. Given the close association between adiposity and metabolic homeostasis, coupled with our previous work demonstrating the ability of 17α-E2 to improve metabolic parameters (Stout et al., 2017b; Steyn et al., 2018), we also assessed several metabolic variables in these studies. Similar to the mass and adiposity data described above, male WT mice receiving 17α-E2 displayed significant improvements in fasting insulin (Figure 3B), HbA1C (Figure 3C), and glucose tolerance (Figure 3D–E, Figure 3—figure supplement 1), whereas male ERα KO mice receiving 17α-E2 failed to recapitulate these findings. Interestingly, despite the masses of the male WT 17α-E2 treatment group being nearly 15 grams greater than those of the male WT chow-fed controls, glucose tolerance was essentially identical between these groups, thereby indicating that 17α-E2 restores metabolic flexibility in the presence of obesity in male mice (Figure 3D–E, Figure 3—figure supplement 1). We also evaluated the effects of 17α-E2 on metabolic parameters in female WT and ERα KO mice provided a standard chow diet. In contrast to the males, we chose not to subject female WT and ERα KO mice to HFD because female ERα KO mice spontaneously develop obesity due to the ablation of ERα (Manrique et al., 2012; Vidal et al., 1999). Given that the female ERα KO mice are already in a challenged state, HFD would further exacerbate mass and adiposity differences between ERα KO and WT female mice. We found that 17α-E2 failed to elicit improvements in mass, adiposity, calorie consumption, or metabolic parameters in female mice of either genotype (Figure 3—figure supplement 2). The positive effects of 17α-E2 in male mice led us to speculate that the liver may play a key role in modulating 17α-E2-mediated effects on systemic metabolic homeostasis. Importantly, several
Figure 2. ERα is required for 17α-E2 to reduce mass, adiposity, and calorie intake in male mice. (A) Percent change in mass (mean ± SEM, two-way repeated measures ANOVA with Holm-Sidak post-hoc; *p<0.05, **p<0.005 between WT HFD and WT HFD+17α), (B) Mass at baseline (week 0, solid) and week 14 (striped) (mean ± SEM, two-way repeated measures ANOVA with Holm-Sidak post-hoc; *p<0.05, **p<0.005), (C) Percent change in fat mass (mean ± SEM, two-way repeated measures ANOVA with Holm-Sidak post-hoc; *p<0.05, **p<0.005), (D) Fat mass at baseline (week 0; solid) and week 14 (striped) (mean ± SEM, two-way repeated measures ANOVA with Holm-Sidak post-hoc; *p<0.05, **p<0.005), and (E) Average daily calorie intake per week in WT and ERα KO mice provided 45% HFD (TestDiet 58V8)±17α-E2 (14.4ppm) (mean ± SEM, two-way repeated measures ANOVA with Holm-Sidak post-hoc; *p<0.05, **p<0.005).
studies have implicated hepatic ERα in the regulation of glucose homeostasis, insulin sensitivity, and crosstalk with hypothalamic neurons that modulate metabolism and feeding behavior (Meda et al., 2020; Torre et al., 2017; Barros and Gustafsson, 2011).

Figure 3. 17α-E2 reverses obesity-related metabolic dysfunction in male WT, but not ERα KO, mice. (A) Fasting glucose (mean ± SEM, two-way repeated measures ANOVA), (B) Fasting insulin (mean ± SEM, two-way repeated measures ANOVA with Holm-Sidak post-hoc; *p<0.05, **p<0.005), and (C) glycosylated hemoglobin (HbA1c) at baseline (week 0; solid) and week 14 (striped) in WT and ERα KO mice provided 45% HFD (TestDiet 58V8)±17α-E2 (14.4 ppm) (mean ± SEM, two-way repeated measures ANOVA with Holm-Sidak post-hoc; *p<0.005). (D) Glucose tolerance testing (GTT; 1 mg/kg) (mean ± SEM, two-way repeated measures ANOVA with Holm-Sidak post-hoc; *p<0.05 between WT HFD and WT HFD+17α), and (E) GTT AUC during week 10 of the study (mean ± SEM, two-way ANOVA with Holm-Sidak post-hoc; *p<0.05). Age-matched, male WT, chow-fed (TestDiet 58YP) mice were also evaluated as a normal-weight reference group and the corresponding means are depicted as dashed gray lines. n = 9–10 (WT HFD), 8–10 (WT HFD+17α), 9–10 (KO HFD), 8–10 (KO HFD+17α), 12–15 (WT Chow).

The online version of this article includes the following figure supplement(s) for figure 3:

**Figure supplement 1.** 17α-E2 reverses obesity-related metabolic dysfunction in male WT, but not ERα KO, mice.

**Figure supplement 2.** 17α-E2 fails to alter metabolic parameters in WT or ERα KO female mice.

---

**Figure 2 continued**

Holm-Sidak post-hoc; *p<0.05, **p<0.005). Age-matched, male WT, chow-fed (TestDiet 58YP) mice were also evaluated as a normal-weight reference group and the corresponding means are depicted as dashed gray lines. n = 10 (WT HFD), 10 (WT HFD+17α), 9 (KO HFD), 10 (KO HFD+17α), 12–15 (WT Chow).
17α-E2 improves liver disease pathology in an ERα-dependent manner in male mice

We previously reported that 17α-E2 alters hepatic lipid deposition and DNA damage responses in male mice through unknown mechanisms (Stout et al., 2017b). In the current study, we sought to determine if these findings are mediated through ERα. We found that 17α-E2 significantly reduced liver mass and steatosis in male WT, but not ERα KO mice, as evidenced by reductions in oil-red-O positivity, fatty acid content, and triglyceride accumulation (Figure 4, Figure 4—figure supplement 1). These observations were accompanied by significant alterations in gene expression associated with de novo lipogenesis (fatty acid synthase [Fasn]) and β-oxidation (peroxisome proliferator-activated receptor alpha [Ppara]; sterol regulatory element binding transcription factor 1 [Srebf1]) (Figure 4—figure supplement 1). These findings are similar to previous reports showing that 17β-E2 acts through ERs to modulate the expression and activity of genes that regulate hepatic lipid metabolism (Della Torre et al., 2016; Stubbins et al., 2012; Zhang et al., 2013). Interestingly, despite seeing overall reductions in hepatic fatty acid content with 17α-E2 treatment in male WT mice (Figure 4C), we also observed elevations in specific fatty acids in these mice as compared to WT HFD controls. Notably, arachidonic acid (AA, 20:4n6) and docosahexaenoic acid (DHA, 22:6n3), both of which are precursors for eicosanoid, resolvin, and protectin production (Szefel et al., 2015; Kohli and Levy, 2009), were found to be increased by 17α-E2 treatment in male WT mice (Figure 4—figure supplement 2). Our findings are aligned with a previous report by Garratt et al. showing that 17α-E2 increases AA and DHA in liver (Garratt et al., 2018). None of the 17α-E2-mediated changes in fatty acid profiles were observed in male ERα KO mice receiving 17α-E2. In response to the elevations in AA and DHA with 17α-E2 treatment, we also assessed circulating eicosanoids. We found that 17α-E2 treatment also mildly altered several circulating eicosanoid concentrations in male WT mice (Supplementary file 3). Many of these have been linked to changes in inflammatory signaling (Kiss et al., 2010; Gilroy et al., 2016), although the role they are playing in 17α-E2-mediated effects of on metabolism and/or aging remain unclear.

Due to the association between obesity-related hepatic steatosis and the onset of fibrosis, we assessed collagen deposition by trichrome staining and found that 17α-E2 reduced this in male WT, but not ERα KO, mice (Figure 5A). We also observed significant suppression of several transcripts associated with liver fibrosis in male WT mice receiving 17α-E2, including collagen type 1 alpha 1

![Figure 4](image)

**Figure 4.** 17α-E2 reverses obesity-related hepatic steatosis in an ERα-dependent manner in male mice. (A) Liver mass (mean ± SEM, two-way ANOVA with Holm-Sidak post-hoc, *p<0.05). (B) Representative liver oil-red-O staining. (C) Liver fatty acids (mean ± SEM, two-way ANOVA with Holm-Sidak post-hoc, **p<0.005), and (D) Liver triglycerides in WT and ERα KO mice provided 45% HFD (TestDiet S8V8)±17α-E2 (14.4ppm) for 14 weeks (mean ± SEM, two-way ANOVA with Holm-Sidak post-hoc; **p<0.005). Age-matched, male WT, chow-fed (TestDiet S8YP) mice were also evaluated as a normal-weight reference group and the corresponding means are depicted as dashed gray lines. n = 4–10 (WT HFD), 4–9 (WT HFD+17α), 4–9 (KO HFD), 4–10 (KO HFD+17α), 4–15 (WT Chow).

The online version of this article includes the following figure supplement(s) for figure 4:

**Figure supplement 1.** 17α-E2 alters markers of lipid and glucose homeostasis predominantly through ERα in male mice.

**Figure supplement 2.** 17α-E2 alters the hepatic fatty acid profile in male WT, but not ERα KO, mice.
17α-E2 reverses obesity-related liver fibrosis and insulin resistance in an ERα-dependent manner in male mice. (A) Representative liver Masson’s trichrome staining for collagen and (B) Liver transcriptional markers of fibrosis in WT and ERα KO mice provided 45% HFD (TestDiet 58V8) ± 17α-E2 (14.4ppm) for 14 weeks (box plots depict total range of fold changes in gene expression with mean shown as a horizontal black line, Benjamini–Hochberg multiple testing correction, two-way ANOVA with Holm-Sidak post-hoc; *p<0.05, **p<0.005). (C) Schematic of in vivo insulin stimulation (2mU/g) in fasting mice, (D) Representative liver immunoblots, and (E) Quantification of phospho/total (p/t) AKT (pS473) and FOXO1 (pS256) in WT and ERα KO mice provided 60% HFD (TestDiet 58Y1) ± 17α-E2 (14.4ppm) for 12 weeks (mean ± SEM, Benjamini-Hochberg multiple testing correction, two-way ANOVA with Holm-Sidak post-hoc; **p<0.005). Age-matched, male WT, chow-fed (TestDiet 58YP) mice were also evaluated as a normal-weight reference group and the corresponding means are depicted as dashed gray lines. n = 7–10 (WT HFD), 8–9 (WT HFD+17α), 7–10 (KO HFD), 10 (KO HFD +17α), 7–11 (WT Chow).

(Col1a1) (Hayashi et al., 2014; Lua et al., 2016), cyclin-dependent kinase inhibitor 1A (Cdkn1a) (Crary and Albrecht, 1998; Yang et al., 2020), matrix metallopeptidase 1 (Mmp1) (Lichtinghagen et al., 2003), matrix metallopeptidase 12 (Mmp12) (Madala et al., 2010), monocyte chemoattractant protein 1 (Ccl2) (Glass et al., 2018; Baeck et al., 2012), C-X-C motif chemokine ligand 1 (Cxcl1) (Yang et al., 2017), growth differentiation factor 15 (Gdf15) (Koo et al., 2018), and
TNF receptor superfamily member 1A (Tnfrsf1a) (Grattaglione et al., 2019; Figure 5B). Transcripts shown to be predicative of hepatic insulin resistance (follistatin [Fst], inhibin subunit beta E [Inhbe], insulin receptor substrate 2 [Irs2]) (Tao et al., 2018; Parks et al., 2015) and gluconeogenic plasticity (phosphoenolpyruvate carboxykinase 1 [Pck1], pyruvate kinase [Pkm]) (Xiong et al., 2011) were also beneficially modulated by 17α-E2 in male WT mice (Figure 4—figure supplement 1). To confirm that 17α-E2 improves hepatic insulin sensitivity, we also evaluated phosphorylation status of AKT and FOXO1 in livers from male WT and ERα KO mice following the administration of an insulin bolus (Figure 5C). We found dramatic improvements in phosphorylated AKT (pS473) and FOXO1 (pS256) in male WT mice treated with 17α-E2 (Figure 5D–E), whereas these benefits were not observed in male ERα KO mice. Our findings are aligned with previous reports demonstrating that hepatic ERα plays a critical role in regulating insulin sensitivity in the liver of male mice (Yan et al., 2019; Guillaume et al., 2019; Qiu et al., 2017; Zhu et al., 2014). Collectively, these findings suggest that the liver is highly responsive to 17α-E2 and that hepatic ERα is likely the signaling mechanism by which 17α-E2 prevents and reverses steatosis, fibrosis, and insulin resistance.

Despite our findings demonstrating that 17α-E2 reduces calorie intake and improves liver disease parameters in male mice in an ERα-dependent manner, it has historically been unclear if the benefits attributed to 17α-E2 occur primarily due to long-term reductions in calorie intake. Moreover, it remains unclear if 17α-E2 acts in a tissue-specific manner and if these observations would also occur in other mammalian species. To address these questions, we subsequently evaluated the effects of acute 17α-E2 administration during hyperinsulinemic-euglycemic clamps in male WT outbred rats. These experiments allowed us to evaluate tissue-specific insulin-sensitivity following acute 17α-E2 exposure, thereby circumventing long-term effects of the compound including reductions in calorie intake.

**Acute 17α-E2 administration improves hepatic insulin sensitivity in male rats**

The hyperinsulinemic-euglycemic clamp is the gold-standard for assessing insulin action in vivo (Ayala et al., 2010). Animals are fasted overnight prior to receiving a constant infusion of insulin and a variable infusion of [3-3H] glucose to maintain a euglycemia throughout the clamping period. Blood samples are frequently obtained to assess glucose concentration and adjust glucose infusion rates (GIRs) to maintain euglycemia, thereby allowing the calculation of insulin sensitivity to be done. Our first set of experiments in male rats sought to determine if acute peripheral infusions of 17α-E2 modulated metabolic parameters during hyperinsulinemic-euglycemic clamps (Figure 6A). We found that acute peripheral administration of 17α-E2 significantly increased systemic insulin responsiveness as compared to vehicle controls, which is indicated by increased GIRs (Figure 6B). These studies also determined that peripheral 17α-E2 administration robustly suppressed hepatic gluconeogenesis as compared to vehicle controls (Rg; Figure 6C–D), whereas glucose disposal rates (Rd; Figure 6E) were essentially identical between groups under clamped conditions. These data indicate that 17α-E2 beneficially modulates metabolic parameters independent of reductions in calorie intake and adiposity. Furthermore, these findings strongly suggest that the liver is a primary site where 17α-E2 acts to improve metabolic homeostasis due to gluconeogenesis being tightly controlled by hormonal actions on hepatocytes (Zhang et al., 2018). However, it also well established that the hypothalamus can directly modulate gluconeogenesis in the liver through hepatic innervation (Timper and Brüning, 2017); therefore, we sought to determine if acute intracerebroventricular (ICV) delivery of 17α-E2 (Figure 6F) could modulate metabolic parameters similarly to that observed during peripheral 17α-E2 administration. Interestingly, we found that central administration of 17α-E2 essentially phenocopied the effects of peripheral 17α-E2 infusion with regard to GIRs and suppression of hepatic gluconeogenesis (Figure 6G–I). These findings suggest that 17α-E2 likely acts through hypothalamic neurons to regulate hepatic gluconeogenesis. Indeed, agouti-related peptide/neuropeptide Y (AgRP/NPY) and pro-opiomelanocortin (Pomc) neurons are known to regulate hepatic glucose production (Könner et al., 2007; Ruud et al., 2017; Pocai et al., 2005a; Pocai et al., 2005b; Dodd et al., 2018) and both neuronal populations express ERα (Smith et al., 2013; Skinner and Herbison, 1997; Xu et al., 2011; Acosta-Martinez et al., 2007; Stinicic et al., 2018; Kelly and Rennkleiev, 2015; Smith et al., 2014). Collectively, the hyperinsulinemic-euglycemic clamp studies revealed that 17α-E2 definitively modulates metabolic homeostasis in an acute manner and suggests
that the liver and hypothalamus are two primary sites of action for the regulation of metabolic parameters by 17α-E2.

Discussion

17α-E2 has recently been found to increase median lifespan in male mice through uncharacterized mechanisms (Strong et al., 2016; Harrison et al., 2014). We and others have shown that metabolic improvements by 17α-E2 may underlie the lifespan extending effects. In these studies, we sought to determine the role of ERα in 17α-E2-mediated transcriptional effects in vitro and metabolic effects in vivo. Although previous studies have shown that 17α-E2 has limited binding affinity for ERα, it remains unclear if 17α-E2 can induce transcriptional and physiological alterations in this manner.

Given the close association between metabolic improvements and ERα activity, we hypothesized that 17α-E2 signals through ERα to elicit beneficial health outcomes. In these studies, we utilized U2OS cells stably expressing ERα and ERα global knockout mice to assess the involvement of this receptor in mediating 17α-E2 effects. Results from these studies demonstrate that ERα is a target for the treatment of aging and chronic diseases in males.

Given the similarities between the metabolic benefits observed in vivo with 17α-E2 treatment and the established body of literature linking ERα activity to systemic metabolic regulation (Barros and Gustafsson, 2011), we utilized a well-established cell line model to globally assess the ERα cistrome and transcriptome following 17α-E2 and 17β-E2 treatment. We found that, regardless of dose, 17α-E2 and 17β-E2 elicited the same pattern of ERα genomic binding loci and these loci shared the same DNA motif enrichments. Additionally, activation and suppression of gene expression were similar with both 17α-E2 and 17β-E2 exposure and were independent of dosage. This provides strong evidence that 17α-E2 is signaling through ERα to elicit beneficial outcomes, which is contrary to
what other reports have suggested (Harrison et al., 2014; Garratt et al., 2017; Garratt et al., 2018; Toran-Allerand et al., 2002; Toran-Allerand et al., 2005; Toran-Allerand, 2005). Toran-Allerand et al. reported that 17α-E2 signals through a novel receptor in the brain, which they termed ER-X (Toran-Allerand et al., 2002; Toran-Allerand, 2005). Although our findings appear to dispute this notion, several reports have shown that ERα exists and functions as multiple alternatively spliced variants (Flouriot et al., 1998; Wang et al., 2005; Taylor et al., 2010; Zhang et al., 2016; Lin et al., 2013). Therefore, we speculate that ER-X may have been a truncated, alternatively spliced, form of ERα, which nonetheless causes the same genomic and transcriptomic effects. These findings led us to investigate how ERα may modulate 17α-E2-induced benefits in vivo using ERα global KO mice.

In alignment with our previous reports (Stout et al., 2017b; Steyn et al., 2018), 17α-E2 reduced calorie intake, body mass, adiposity, and obesity-related metabolic perturbations in male WT mice. Conversely, 17α-E2 failed to elicit these beneficial effects in ERα KO mice, further supporting our hypothesis that ERα is the receptor by which 17α-E2 signals to induce beneficial metabolic outcomes. These observations are similar to how ERα is known to mediate the actions of endogenous estrogens on metabolic parameters in females (Barros and Gustafsson, 2011). In particular, 17β-E2 acts through ERα to regulate systemic insulin sensitivity, lipid distribution, thermogenesis, and hypothalamic anorexigenic pathways (Barros and Gustafsson, 2011; Stinic et al., 2018; López and Tena-Sempere, 2015). The loss of endogenous estrogen action due to menopause in humans or ovariectomy (OVX) in rodents eliminates these beneficial effects and elicits metabolic perturbations (Stefanska et al., 2015). Moreover, OVX following sexual maturation has also been shown to reduce lifespan in female mice (Benedusi et al., 2015), indicating that endogenous estrogens regulate lifespan in females, which we surmise is at least partially mediated through ERα.

In the current study, 17α-E2 failed to induce beneficial metabolic effects in female mice of either genotype, which we postulate is due to endogenous 17β-E2 saturating ERα in female WT mice, thereby limiting the potential benefits of 17α-E2 treatment. This interpretation is supported by our recent report showing that OVX renders WT female mice responsive to the beneficial effects of 17α-E2 on adiposity and bone mass (Mann et al., 2020), both of which are regulated by ERα activity (Heine et al., 2000; Khosla and Monroe, 2018). In males, very few studies have evaluated the role of ERα in metabolism, although a few recent reports have suggested that ERα plays tissue-specific roles, particularly in the liver, by regulating glucoregulatory pathways (Allard et al., 2019; Yan et al., 2019; Guillaume et al., 2019; Qiu et al., 2017; Meda et al., 2020; Zhu et al., 2014). These studies, coupled with our current findings, led us to speculate that 17α-E2 may be signaling through ERα in the liver to reverse metabolic disease and potentially extend healthspan and/or lifespan in males.

The liver is a major regulator of systemic metabolic homeostasis. Obesity and advancing age often promote a variety of liver conditions, including steatosis, fibrosis, and insulin resistance; all of which are associated with hallmarks of aging (Hunt et al., 2019), including cellular senescence (Ogrodnik et al., 2017), epigenetic alterations (Horvath et al., 2014), and dysregulated nutrient-sensing (López-Otín et al., 2013). We have previously shown that 17α-E2 can reduce hepatic steatosis, hepatic insulin resistance, and hepatocyte DNA damage through unknown mechanisms (Stout et al., 2017b). In the present study, we sought to determine if these findings are mediated through ERα. We found that 17α-E2 dramatically reduced liver mass and lipid content. As expected, these observations were not seen in ERα KO mice, providing further support for the hypothesis that 17α-E2 regulates systemic metabolic parameters through ERα. Interestingly, our findings suggest that 17α-E2 suppresses de novo lipogenesis and increases β-oxidation, predominantly in an ERα-dependent manner. This is aligned with previous reports showing that 17β-E2 can modulate hepatic lipid dynamics through both genomic and non-genomic actions (Pedram et al., 2016), leading to altered expression of rate limiting enzymes that control de novo lipogenesis (Zhang et al., 2013) and β-oxidation (Camporez et al., 2013). Reports have also shown that 17β-E2 can increase triglyceride export, thereby decreasing hepatic lipid deposition (Zhu et al., 2013). Although we did not directly assess cholesterol profiles in these studies, we speculate that 17α-E2 may partially reduce hepatic steatosis by increasing VLDL synthesis and/or triglyceride incorporation into VLDL. Additional studies will be needed to confirm how 17α-E2 alters hepatic lipoprotein dynamics.

Hepatic steatosis promotes liver fibrosis, which exacerbates hepatic insulin resistance (Kim et al., 2015). Endogenous estrogens and hormone replacement therapies in post-menopausal women
have been shown to serve a protective role on liver function (Stubbins et al., 2012; Camporez et al., 2013; Zhu et al., 2013; Rossi et al., 2004; Brussard et al., 1997). Additionally, male humans are at a higher risk of developing hepatic steatosis and fibrosis as compared to age-matched females (Guy and Peters, 2013; GBD 2017 Cirrhosis Collaborators and Collaborators, 2020). In addition to reducing hepatic lipid deposition in male WT mice in the current studies, 17α-E2 also dramatically suppressed transcriptional and histological markers of hepatic fibrosis in an ERα-dependent manner. We also determined that 17α-E2 improved hepatic insulin sensitivity in male WT, but not ERα KO, mice. Several transcriptional markers associated with hepatic insulin resistance were suppressed in male WT mice receiving 17α-E2, whereas this suppression was almost entirely absent in ERα KO mice. Subsequent studies employing insulin stimulation prior to euthanasia also revealed that 17α-E2 robustly increased liver AKT and FOXO1 phosphorylation in male WT mice, indicating a reversal of obesity-related hepatic insulin resistance and increased control of gluconeogenesis. These findings clearly demonstrate that 17α-E2 modulates hepatic insulin sensitivity in an ERα-dependent manner. These observations are aligned with previous reports showing that 17β-E2 acts through ERα to improve glucoregulation (Meda et al., 2020; Zhu et al., 2013). This provides further support that 17α-E2 is eliciting metabolic improvements through ERα that are specific to the liver. Therefore, hepatic ERα may be a promising target for the development of therapeutics to alleviate metabolic disease in males. Future studies utilizing cell-type-specific ablation of ERα in the liver will be needed to unravel these possibilities.

Despite the robust effects of 17α-E2 on liver function, it remained unclear if 17α-E2 directly modulates hepatic insulin sensitivity or if these benefits were a secondary response to prolonged reductions in calorie intake, adiposity, and lipid redistribution. To test this, we performed hyperinsulinemic-euglycemic clamps, in conjunction with acute infusions of 17α-E2 in male WT rats. We found that peripheral infusions of 17α-E2 improved hepatic insulin sensitivity almost immediately, as evidenced by a greater suppression of hepatic glucose production in rats receiving 17α-E2 as compared to vehicle controls. Additionally, we did not observe improvements in glucose disposal, thereby indicating that 17α-E2 does not acutely increase systemic insulin-stimulated glucose uptake. This observation is aligned with recent literature demonstrating limited involvement of ERα in skeletal muscle insulin sensitivity (Inígó et al., 2020). These data indicate that 17α-E2 primarily alters systemic metabolic homeostasis through the modulation of hepatic gluconeogenesis, which is known to account for 76–87% of glucose production in the body (Cherrington et al., 1994). Although these studies are suggestive of direct actions in the liver, 17α-E2 also has the ability to cross the blood brain barrier and elicit responses in the hypothalamus (Steyn et al., 2018). Given that the hypothalamus can regulate hepatic glucose production (Könner et al., 2007; Ruud et al., 2017; Pocai et al., 2005a; Pocai et al., 2005b; Dodd et al., 2018; Timper and Brüning, 2017), we also evaluated systemic insulin sensitivity following central administration of 17α-E2. These experiments essentially phenocopied the results of the peripheral 17α-E2 infusions, suggesting that the suppression of hepatic gluconeogenesis by 17α-E2 is at least partially mediated by the hypothalamus. A multitude of studies have shown that the arcuate nucleus (ARC) of the hypothalamus plays a critical role in the regulation of hepatic gluconeogenesis through autonomic regulation and vagus nerve activity (Ruud et al., 2017; Pocai et al., 2005a; Zhang et al., 2018; Brandt et al., 2018). Multiple neuronal populations within the ARC are known to be involved in the regulation of hepatic glucose production, including Pomc (Dodd et al., 2018) and AgRP/NPY (Könner et al., 2007; Ruud et al., 2017; Pocai et al., 2005a; Pocai et al., 2005b). Similarly, we have previously shown that the effects of 17α-E2 on calorie intake and adiposity are dependent upon functional Pomc neurons, thereby providing evidence that 17α-E2 can act through the hypothalamus to mediate systemic metabolic parameters (Steyn et al., 2018). However, in the absence of functional Pomc neurons, 17α-E2 was still able to reduce fasting glucose and insulin, suggesting that 17α-E2 modulates peripheral metabolism through multiple mechanisms, which may include alternative neuronal populations. Given that both Pomc (Xu et al., 2011) and AgRP/NPY (Smith et al., 2013; Skinner and Herbison, 1997; Acosta-Martinez et al., 2007; Stincic et al., 2018; Kelly and Ronnekleiv, 2015; Smith et al., 2014; Sar et al., 1990) neurons express ERα, regulate systemic metabolic parameters, and modulate feeding circuitry in a coordinated counter-regulatory fashion, it remains unclear whether 17α-E2 is altering hepatic and systemic metabolic parameters through Pomc and/or AgRP/NPY neurons. Interestingly, a recent report from Debarba et al. demonstrated that 17α-E2 increased hypothalamic ERα expression in the ARC (Debarba, 2020), which further suggests that 17α-E2 signals through
ERα in the hypothalamus. Future studies utilizing hypothalamic cell-type-specific ERα KO models will be needed to disentangle which populations of neurons are required for 17α-E2 to control food intake, peripheral glucose homeostasis, and insulin sensitivity.

Collectively, our findings strongly suggest that 17α-E2 acts through ERα in the liver and/or hypothalamus to modulate metabolic parameters. However, our findings are in contrast to other reports suggesting that 17α-E2 elicits health benefits by modulating androgen metabolism (Garratt et al., 2017; Garratt et al., 2018; Garratt and Stout, 2018). Garratt et al. reported that responsiveness to 17α-E2 was significantly attenuated in castrated male mice (Garratt et al., 2018), which the authors proposed may indicate 17α-E2 acts as a 5α-reductase inhibitor (Schriefers et al., 1991) to prevent the conversion of testosterone into dihydrotestosterone (DHT). 17α-E2 is known to be a mild 5α-reductase inhibitor that is prescribed as a topical treatment for androgenetic alopecia (Orfano and Vogels, 1980). 5α-Reductase inhibition could conceivably elicit beneficial metabolic effects by either reducing the concentration of DHT, which has been shown to decrease adiposity (Movéra-Skrtic et al., 2006; Bolduc et al., 2004), or by promoting greater aromatization of testosterone to 17β-E2 (Veldhuis et al., 2009), which has been linked to improvements in metabolic parameters (Rubinow, 2017). If true, this would imply that the benefits of 17α-E2 are occurring in an indirect manner. However, the dose of 17α-E2 used in the vast majority of these studies, does not induce dramatic feminization of the sex hormone profiles in male mice (Stout et al., 2017b), which leads us to speculate that 17α-E2 is acting in a direct manner through ERα rather than indirectly through androgen modulation. Furthermore, studies in male rodents (Livingstone et al., 2015; Dowman et al., 2013) and humans Wei et al., 2019 demonstrate that 5α-reductase inhibition or deficiency increases insulin resistance and hepatic steatosis and fibrosis, which are contradictory to the effects of 17α-E2 treatment in all of our studies utilizing male mice (Stout et al., 2017b; Steyn et al., 2018; Miller, 2020; Sidhom et al., 2020). Despite these contrasting observations, the studies by Garratt et al. do provide important insights into the interconnected and underappreciated relationship between androgen- and estrogen-signaling pathways and their roles in metabolism and aging. For instance, several recent reports have demonstrated interactions between the androgen receptor (AR) and ERα (D’Amato et al., 2016; Panet-Raymond et al., 2000; Peters et al., 2009), which suggests that modulation of one may affect function of the other. Additional factors to consider when comparing and contrasting our studies from those of Garratt et al. are differences in the length of study, age, and obesity status of the mice, and counterregulatory and/or compensatory effects of castration. Notably, it is plausible that 17α-E2 could be inducing metabolic benefits and lifespan-extending effects through several distinct mechanisms, including direct actions through ERα, suppression of DHT production, and/or aromatization of testosterone. Future studies will be needed to discern the potentially interdependent nature of 17α-E2 actions on ERα and androgen metabolism in metabolic improvement and lifespan extension.

There are a few notable caveats to our studies. First, we utilized constitutive global ERα KO mice, which have been shown to display varying degrees of compensatory ERβ activity due to the absence of ERα during development (Sánchez-Criado et al., 2012; Rosenfeld et al., 1998). However, if compensatory ERβ expression was playing a role in our study, we likely would not see a complete attenuation of 17α-E2-mediated effects. As such, the results of our studies clearly indicate that ERα is the primary receptor by which 17α-E2 signals. Another potential concern of the model is that ERα KO mice are known to have elevated endogenous testosterone levels (Gould et al., 2007), although the studies by Garratt et al. would suggest that higher testosterone levels could potentially render the male mice more responsive to 17α-E2, whereas we observed the opposite. Future studies utilizing inducible Cre models to knockdown ERα post-sexual development may be considered if it is determined that Cre induction and subsequent ERα ablation is consistent throughout multiple organ systems, which has been shown to be inconsistent in other reports (Murray et al., 2012). Despite these minor concerns related to the model, the use of the constitutive global ERα KO was undeniably the best option for these studies. However, it must also be noted that female mice present a greater phenotypic response than males to the ablation of ERα, thereby exacerbating obesity and metabolic dysfunction which makes comparisons to female WT mice as well as their male littermates problematic (Manrique et al., 2012; Vidal et al., 1999). For this reason, we chose not to provide HFD to female mice in these studies. Regardless, 17α-E2 still failed to elicit beneficial responses in female mice of either genotype (WT or ERα KO), which is aligned with previous reports demonstrating a lack of effect of 17α-E2 in intact females (Garratt et al., 2017; Garratt et al., 2018). We also
recently reported that OVX renders female mice responsive to several of the benefits conferred by 17α-E2 treatment in male mice (Mann et al., 2020). These observations, coupled with the genomic data presented herein, support the hypothesis that endogenous 17β-E2 actions on ERα diminishes potential benefits of 17α-E2 in intact female mice. However, future studies will be needed to definitively determine if female mice subjected to diet-induced obesity will display responsiveness to 17α-E2 once severe metabolic dysfunction has emerged. Lastly, the current studies were relatively short in duration and it remains unclear if metabolic improvements with 17α-E2 treatment are required for the lifespan extension effects of the compound. Although several other studies have evaluated the long-term effects of 17α-E2 (Strong et al., 2016; Harrison et al., 2014; Garratt et al., 2017; Garratt et al., 2018), a shorter treatment duration was effective for testing our hypothesis in these studies. Similarly, given the close relationship between metabolic homeostasis, sex hormones, and longevity (López-Otín et al., 2013; Barros and Gustafsson, 2011), we surmise that future studies evaluating the effects of ERα on male lifespan in the presence or absence of 17α-E2 will be needed. Although our current report does not provide direct evidence that ERα modulates the lifespan extending effects of 17α-E2, it does provide insight into the involvement of hepatic and/or hypothalamic ERα on 17α-E2-mediated metabolic effects in male mice.

In summary, the data presented herein are the first to show that 17α-E2 and 17β-E2 induce nearly identical ERα chromatin association patterns and transcriptional activity. Moreover, we demonstrate that the metabolic benefits of 17α-E2 in male mice are ERα-dependent. We also provide evidence that strongly suggests 17α-E2 acts through the liver and hypothalamus to regulate metabolic homeostasis in male mice. These effects were mirrored by studies in male WT rats receiving 17α-E2, indicating that 17α-E2 can modulate metabolism almost instantaneously and that these effects are not limited to a single mammalian species. Future studies will be needed to confirm that 17α-E2 acts predominantly through ERα in a cell-type-specific manner in the liver and hypothalamus to modulate systemic metabolic homeostasis. It is also imperative that we determine if ERα exclusively modulates the lifespan-extending effects of 17α-E2 in male mice. Another potential avenue of investigation that remains unresolved is whether 17α-E2 acts through ERα in a genomic or non-genomic manner to modulate health parameters. Potential interactions between androgen and estrogen signaling must also be considered when evaluating the effects of 17α-E2 on metabolism and lifespan. These studies will provide additional insight into mechanisms of metabolic improvement and lifespan extension by 17α-E2. Our studies provide critical insight into the molecular mechanisms by which 17α-E2 elicits metabolic benefits in males, which were previously unknown and may underlie its lifespan-extending effects.

Materials and methods

## Key resources table

| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|---------------------|-------------|------------------------|
| Genetic reagent (M. musculus)     | B6N(Cg)-Esr1tm4.2Ksk/J | The Jackson Laboratory | Stock No:026176; RRID:IMSR_JAX:026176 | ERα (Esr1) KO mice |
| Cell line (Homo sapiens)          | U2OS Cells | ATCC | HTB-96; RRID:CVCL_0042 | PMID:15802376; PMID:14505348 |
| Antibody                          | anti-FLAG M2 (Mouse monoclonal) | Sigma-Aldrich | F1804 | IP: 1 uL per pull-down (1 mg/mL) |
| Commercial assay or kit           | Protein G Dynabeads | Applied Biosystems/ Thermofisher Scientific | 10003D | IP: 30 uL per IP |
| Chemical compound, drug          | 17α-E2 | Steraloids, Inc | E0870-000 | |
| Chemical compound, drug          | Novolin R 100 U/ml | Novolin | | 2mU/g |
| Other (diet)                      | Chow; TestDiet 58YP | TestDiet | TestDiet 58YP | |
| Other (diet)                      | HFD; TestDiet 58V8 | TestDiet | TestDiet 58V8 | HFD 45% by kcal |
| Other (diet)                      | HFD; TestDiet 58Y1 | TestDiet | TestDiet 58Y1 | HFD 60% by kcal |

Continued on next page
| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|--------------------|-------------|------------------------|
| Commercial assay or kit | Mouse Ultrasensitive Insulin ELISA | ALPCO | Cat# 80-INSMSU-E01; RRID:AB_2792981 |  |
| Commercial assay or kit | Free Glycerol Agent | Sigma-Aldrich | Sigma F6428 |  |
| Commercial assay or kit | Triglyceride Reagent | Sigma-Aldrich | Sigma F6428 |  |
| Commercial assay or kit | Glycerol Standard | Sigma-Aldrich | Sigma G1394 |  |
| Antibody | anti-pS473 AKT (Rabbit polyclonal) | Abcam | Cat# ab81283; RRID:AB_2224551 | WB: (1:3000) |
| Antibody | Anti-pan-AKT (Rabbit polyclonal) | Abcam | Cat# ab179463; RRID:AB_2810977 | WB: (1:10000) |
| Antibody | Anti-pS256 FOXO1 (Rabbit polyclonal) | Abcam | Cat# ab131339; RRID:AB_11159015 | WB: (1:1000) |
| Antibody | Anti-FOX01a (Rabbit polyclonal) | Abcam | Cat# ab52857; RRID:AB_869817 | WB: (1:1000) |
| Antibody | Anti-GAPDH (Rabbit polyclonal) | Abcam | Cat# ab9485; RRID:AB_307275 | WB: (1:15000) |
| Commercial assay or kit | TaqMan Gene Expression Master Mix | Applied Biosystems/Thermofisher Scientific | 4369542 |  |
| Sequenced-based reagent | qPCR primer Mmp1 | Integrated DNA Technologies | Mm.PT.58.42286812 Ref Seq: NM_008607(1) | Exon 5–6 |
| Sequenced-based reagent | qPCR primer Mmp12 | Integrated DNA Technologies | Mm.PT.58.31615472 Ref Seq: NM_008605(1) | Exon 8–9 |
| Sequenced-based reagent | qPCR primer Ccl2 | Integrated DNA Technologies | Mm.PT.58.42151692 Ref Seq: NM_011333(1) | Exon 1–3 |
| Sequenced-based reagent | qPCR primer Srebfl | Integrated DNA Technologies | Mm.PT.58.8508227 Ref Seq: NM_011480(1) | Exon 1–2 |
| Sequenced-based reagent | qPCR primer Pck1 | Integrated DNA Technologies | Mm.PT.58.11992693 Ref Seq: NM_011044(1) | Exon 3–4 |
| Sequenced-based reagent | qPCR primer Cdkn1a | Integrated DNA Technologies | Mm.PT.58.17125846 Ref Seq: NM_007669(1) | Exon 2–3 |
| Sequenced-based reagent | qPCR primer Ppara | Integrated DNA Technologies | Mm.PT.58.9374886 Ref Seq: NM_00113418(2) | Exon 8–9 |
| Sequenced-based reagent | qPCR primer Cxcl1 | Integrated DNA Technologies | Mm.PT.58.42076891 Ref Seq: NM_008176(1) | Exon 2–4 |
| Sequenced-based reagent | qPCR primer Col1a1 | Integrated DNA Technologies | Mm.PT.58.7562513 Ref Seq: M_007742(1) | Exon 1–2 |
| Sequenced-based reagent | qPCR primer Tnfrsf1a | Integrated DNA Technologies | Mm.PT.58.28810479 Ref Seq: NM_011609(1) | Exon 5–7 |
| Software, algorithm | SigmaPlot 12.5 | Systat Software | RRID:SCR_003210 | statistical analyses |
| Software, algorithm | ImageJ | ImageJ | RRID:SCR_003070 | histological quantification |
| Software, algorithm | Image Studio | LI-COR | RRID:SCR_015795 | western blot quantification |
| Software, algorithm | RStudio | GenomicAlignments DiffBind DESeq2 GenomicRanges | RRID:SCR_000432 | Peak Calling Differential expression Differential binding |
| Software, algorithm | Bowtie2 MACS2 Bedtools Samtools Picard-tools Trimmomatic | Bowtie2 MACS2 Bedtools Samtools Picard-tools Trimmomatic |  | Alignment, Peak Calling, trimming, duplicate identification |
U2OS cells
U2OS osteosarcoma cells stably expressing flag-tagged ERα (U2OS-ERα) under the control of doxycycline (dox)-inducible promoter (Monroe et al., 2003) were utilized for the studies described here. U2OS cells were originally purchased from ATTC and were authenticated using IDEXX BioAnalytics (Westbrook, ME). Cells were also regularly checked for mycoplasma contamination using a PCR-based mycoplasma detection kit from SouthernBiotech (Birmingham, AL) and were confirmed to be negative. U2OS-ERα cells were cultured in phenol-free αMEM medium supplemented with 10% HyClone TM charcoal/dextran stripped FBS (GE Healthcare Life Sciences, Pittsburgh, PA), 1% antibiotic/antimycotic, 5 mg/L blasticidin S, and 500 mg/L zeocin in a humidified 37˚C incubator with 5% CO₂. Cells were plated in 12-well plates in the presence of doxycycline to induce ERα expression. The following day, cells were treated for 24 hr with 17β-E2 (10 nM) or 17α-E2 (10 nM and 100 nM) (Steraloids, Newport, RI) in charcoal-stripped FBS-containing media.

ChIP-sequencing
To evaluate patterns of ERα binding agonized by 17α-E2 vs 17β-E2, we performed ChIP-Sequencing. U2OS-ERα cells were harvested 24 hr post-treatment and chromatin immunoprecipitation was performed as previously described (Reese et al., 2018; Nelson et al., 2006). Briefly, ERα was immunoprecipitated overnight at 4˚C using 10 µg of Flag antibody (clone M2, Sigma-Aldrich, St. Louis, MO). Complexes bound to the antibody were captured with protein G Dynabeads (Thermo Fisher Scientific, Waltham, MA), extensively washed, and reverse cross-linked at 65˚C overnight. DNA isolation was performed by phenol/chloroform extraction and was used for ChIP-sequencing library preparation. Libraries were sequenced using paired-end 100 bp reads on the Illumina HiSeq 4000 (GSE151039). Reads were aligned to the human genome (hg19, https://genome.ucsc.edu/cgi-bin/hgGateway) using bowtie2 (Langmead and Salzberg, 2012) and duplicated reads were flagged with Picard-tools (http://broadinstitute.github.io/picard/). ERα-binding peaks were called using MACS2 (Zhang et al., 2008) with recommended settings. Peak genomic location, breadth of coverage, and peak summit location were determined using MACS2. NarrowPeak files containing peak information were used to determine differential ERα binding. First, peaks were centralized around the summit and 250 bp flanking regions were added to the summit location to generate equal 500 bp regions across all experimental groups. Peak files were then used to extract read counts from the aligned de-duplicated BAM file using samtools (Li et al., 2009), read counts were then normalized to total library sequencing depth. To determine differential binding, the R package diffbind was utilized (Ross-Innes et al., 2012). Normalized read counts were log2 transformed and normalized across all experimental groups. Differential binding between treatment groups was determined using negative binomial regression models utilized in the R package DESeq2, statistical significance for pairwise comparisons between experimental groups was determined using Wald test. To account for multiple comparisons, we used Benjamini-Hochberg multiple testing correction (False-discovery rate, FDR). Motif analysis was performed using HOMER with standard settings to identified motifs. Peak regions called for each treatment group were analyzed to identify enriched motifs relative to the entire genome. For pairwise differential motif enrichment or depletion between experimental groups, we utilized a hypergeometric test with the number of sequences with a motif from each group and total number of peaks as total sample size. Motifs that appeared in less than five sequences between both pairwise test groups were removed. Benjamini-Hochberg multiple testing correction was utilized to control for multiple testing (FDR < 0.05).

RNA-sequencing
U2OS-ERα cells were harvested 24 hr post-treatment and RNA was extracted using Trizol and DNase cleanup. RNA libraries were prepared with Illumina’s TrueSeq RNA-Seq library prep according to manufacturer protocol. Libraries were sequenced with 150 bp paired-end reads on the Illumina 4000 platform (Illumina, San Diego, CA) (GSE151039). Sequence quality control was performed with fastQC, Paired reads were trimmed using trimmomatic, and were aligned to the hg19 genome using STAR (Dobin et al., 2013). Differential expression was determined using previously described methods (Hadad et al., 2019). In brief, gene counts were determined with the R package GenomicAlignments ‘summarizeOverlap’ function. Gene counts were then transformed using regularized log
transformation and normalized relative to library size using the DESeq2 (Love et al., 2014) R package. Differential expression was determined using negative binomial generalized linear model using counts ~ treatment model. We performed pairwise differential expression between all experimental groups using Wald test. All comparisons were corrected for multiple testing using Benjamini-Hochberg multiple testing correction method. Differential expression significance threshold was set to FDR corrected p<0.05.

Animal study 1
To determine if ERα is the primary receptor by which 17α-E2 signals to elicit metabolic benefits in vivo, we utilized male global ERα KO and WT littermate mice. Mice were acquired from Dr. Kenneth Korach (National Institute of Environmental Health Sciences [NIEHS]) and were also bred at OUHSC by pairing ERα heterozygous KO mice (JAX; strain #026176). Mice were fed a 45% high-fat diet (HFD) (TestDiet 58V8, 35.5% CHO, 18.3% PRO, 45.7% FAT) from TestDiet (Richmond, IN) for 4 months prior to study initiation to induce obesity and metabolic perturbations. Additionally, age-matched, male WT, chow-fed mice were maintained on TestDiet 58YP (66.6% CHO, 20.4% PRO, 13.0% FAT) throughout the entire study as a healthy-weight reference group. Mice were individually housed with ISO cotton pad bedding, cardboard enrichment tubes, and nestlets at 22 ± 0.5˚C on a 12:12 hr light-dark cycle. Unless otherwise noted, all mice had ad libitum access to food and water throughout the experimental timeframe. At the conclusion of the fattening period, all mice (age: 6–8 months) receiving HFD were randomized within genotype by age, body mass, fat mass, calorie intake, fasting glucose, fasting insulin, and glycosylated hemoglobin (HbA1C) into HFD or HFD+17α (TestDiet 58V8 + 17α-E2, 14.4ppm; Steraloids, Newport, RI) treatment groups for a 14-week intervention. Body mass and calorie intake were assessed daily for the first 4 weeks, followed by body mass and body composition (EchoMRI, Houston, TX) on a weekly basis. At 10 weeks post-treatment, mice were fasted for 5–6 hr and fasting glucose, fasting insulin, HbA1C, and glucose tolerance were assessed. At the conclusion of the study (14 weeks post treatment), mice were euthanized with isoflurane in the fasted state (5–6 hr). Blood was collected into EDTA-lined tubes by cardiac puncture, and plasma was collected and frozen. Tissues were excised, weighed, flash frozen, and stored at −80˚C unless otherwise noted. Small sections of liver were fixed in 4% paraformaldehyde in preparation for paraffin- or cryo-embedding for future analyses. All animal procedures were reviewed and approved by the Institutional Animal Care and Use Committee at OUHSC.

Animal study 2
Although previous studies [Strong et al., 2016; Harrison et al., 2014; Garratt et al., 2017; Garratt et al., 2018] have demonstrated minimal effects of 17α-E2 in female mice, we thought it prudent to determine if the ablation of ERα would alter female responsiveness to 17α-E2. Female WT and ERα KO mice were acquired from Dr. Kenneth Korach (National Institute of Environmental Health Sciences [NIEHS]). Female mice were maintained on Chow TestDiet 58YP (66.6% CHO, 20.4% PRO, 13.0% FAT) and were not subject to HFD feeding due to ERα KO female mice naturally displaying an obesity phenotype. Mice were individually housed with ISO cotton pad bedding, cardboard enrichment tubes, and nestlets at 22 ± 0.5˚C on a 12:12 hr light-dark cycle. Unless otherwise noted, all mice had ad libitum access to food and water throughout the experimental timeframe. At age 9–11 months, female mice were randomized within genotype by age, body mass, fat mass, calorie intake, fasting glucose, fasting insulin, and glycosylated hemoglobin (HbA1C) into Chow or Chow +17α-E2 (TestDiet 58YP + 17α-E2,14.4ppm; Steraloids, Newport, RI) treatment groups. The study was terminated following a 4-week intervention due to a lack of responsiveness to 17α-E2. At the conclusion of the study, mice were euthanized with isoflurane in the fasted state (5–6 hr). Blood was collected into EDTA-lined tubes by cardiac puncture, and plasma was collected and frozen. Tissues were excised, weighed, flash frozen, and stored at −80˚C. All animal procedures were reviewed and approved by the Institutional Animal Care and Use Committee at OUHSC.

Animal study 3
To assess insulin sensitivity within the liver, an additional cohort of ERα KO and WT littermate mice were bred from mice acquired from Jackson Laboratory (JAX; strain #026176), which were generated from identical founder strains in the laboratory of Dr. Korach at NIEHS. Male ERα KO and WT
mice were fed a 60% high-fat diet (HFD; TestDiet 58Y1, 20.3% CHO, 18.1% PRO, 61.6% FAT) for 4 months prior to study initiation to induce obesity and metabolic perturbations. Additionally, as was done in Animal Study 1, age-matched, male WT, chow-fed mice were maintained on TestDiet 58YP (66.6% CHO, 20.4% PRO, 13.0% FAT) throughout the entire study as a healthy-weight reference group. Mice were group housed with corncob bedding, cardboard enrichment tubes, and nestlets at 22 ± 0.5°C on a 12:12 hr light-dark cycle. Unless otherwise noted, all mice had ad libitum access to food and water throughout the experimental timeframe. At the conclusion of the fatting period, all mice (age: 6 months) receiving HFD were randomized within genotype by body mass, fat mass, calorie intake, fasting glucose, and fasting insulin into HFD or HFD+17α (TestDiet 58Y1 + 17α-E2, 14.4ppm; Steraloids, Newport, RI) treatment groups for a 12-week intervention. Prior to being euthanized, mice were fasted (5–6 hr) and IP injected with insulin (Novolin R 100 U/ml; 2mU/g) to assess insulin activity and sensitivity in tissue as previously described (Lu et al., 2012). Each mouse was euthanized with isoflurane 15 min following their insulin injection. Blood was collected into EDTA-lined tubes by cardiac puncture, and plasma was collected and frozen. Tissues were excised, weighed, flash frozen, and stored at −80°C unless otherwise noted. All animal procedures were reviewed and approved by the Institutional Animal Care and Use Committee at OUHSC.

Animal study 4
Hyperinsulinemic-euglycemic clamp experiments, the gold-standard for assessing insulin sensitivity, were performed in male rats to determine if 17α-E2 can acutely modulate insulin sensitivity and glucose homeostasis. FBN-F1 hybrid male rats were acclimated to the animal facilities within the Einstein Nathan Shock Center for 2 weeks prior to undergoing surgeries in preparation for hyperinsulinemic-euglycemic clamp studies. Rats were fed Purina 5001 (58.0% CHO, 28.5% PRO, 13.5% FAT) and were individually housed with corncob bedding at 22 ± 0.5°C on a 14:10 hr light-dark cycle with ad libitum access to food and water. All surgeries were conducted under 2% isoflurane. For clamp studies incorporating central infusions, rats underwent two surgical procedures. First, stereotactic placement of a steel-guide cannula (Plastics One, Roanoke, VA) reaching the 3rd ventricle was performed. The implant was secured in place with dental cement and animals were treated with analgesic as needed. Approximately 14 days later, animals underwent a second surgical procedure to place indwelling catheters into the right internal jugular vein and the left carotid artery, which was also performed for animals undergoing only peripheral clamp studies. Hyperinsulinemic-euglycemic clamp studies incorporating peripheral 17α-E2 infusions were performed as previously described (Einstein et al., 2010). For studies employing peripheral infusions of 17α-E2, 17α-E2 was diluted in sterile saline to a final concentration of 30 ng/µl. Beginning at t = 0 min animals received a primed-continuous infusion of saline or 30 ng/µl 17α-E2 provided as a 3 μg bolus at a rate of 20 μl/min over 5 min, followed by a continuous infusion at a rate of 0.06 ml/hr over 235 min (9.4 ng/hr) for a maintenance dose of 7 μg (total dose 10 μg). Hyperinsulinemic-euglycemic clamp studies with intracerebroventricular (ICV) infusions were performed as previously described (Huffman et al., 2016a). 17α-E2 powder (Steraloids, Newport, RI) was dissolved in DMSO at a concentration of 10 mg/ml and stored at −80°C. For ICV infusions, 17α-E2 was diluted in artificial cerebral spinal fluid (ACSF) to a final concentration of 2 ng/µl. Beginning at t = 0 min, animals received a primed-continuous ICV infusion of ACSF (Veh.) or 17α-E2 (17α) provided as a 15 ng bolus at a rate of 1 μl/min over 7.5 min, followed by a continuous infusion of 56.5 ng at a rate of 0.08 μl/hr over 6 hr (9.4 ng/hr) and a total dose of 71.5 ng. All animal procedures were reviewed and approved by the Institutional Animal Care and Use Committee at the Einstein College of Medicine.

In vivo metabolic analyses in mice
To evaluate the effects of 17α-E2 on metabolic parameters in vivo, we performed several assessments of glucose homeostasis. Unless otherwise noted, all experiments requiring fasting conditions were performed in the afternoon, 5–6 hr following the removal of food at the beginning of the light-cycle as outlined elsewhere (Ayala et al., 2010). To ensure fasting conditions, mice were transferred to clean cages containing ISO cotton padding and clean cardboard enrichment tubes. Non-terminal blood was collected via tail snip. Fasting glucose was evaluated using a Bayer Breeze 2 Blood Glucose Monitoring System (Bayer Global, Leverkusen, Germany). Fasting insulin was evaluated using a Mouse Ultrasensitive Insulin ELISA from Alpco (Salem, NH). HbA1c was assessed by A1C-Now.
Monitoring kits (Bayer, Whippany, NJ). Glucose tolerance tests were performed following a 5 hr fast using an intraperitoneal filtered dextrose injection of 1 g/kg body mass (Huffman et al., 2016b).

Blood glucose was measured immediately pre-injection (time 0) and at 15, 30, 60, 90, and 120 min post-injection.

Liver histology

To evaluate the effects of 17α-E2 treatment on lipid accumulation and fibrosis, we evaluated fixed liver tissue. Tissues were fixed in 4% PFA for 24 hr, cryo-embedding samples were transferred to 30% sucrose for 72 hr and embedded in OCT, paraffin-embedding samples were transferred to 1X PBS for 48 hr, then to 70% ethanol until embedding. Liver oil-red-O and Masson's trichrome staining were performed by the Oklahoma Medical Research Foundation Imaging Core Facility using previously reported methodology (Leonard et al., 2018; Mehlem et al., 2013). Oil-red-O (ORO, Sigma-Aldrich, St. Louis, MO) and H and E counterstaining were performed on cryo-embedded tissues, and were imaged within 6 hr of staining. Red lipid stain was blindly quantified from 10 images per animal using ImageJ software and presented as a lipid to total tissue ratio. Masson's trichrome staining was performed on paraffin embedded liver tissue and was used for qualitative purposes. In brief, slides were stained with Weigert's Iron Hematoxylin (Sigma-Aldrich, St. Louis, MO), washed, stained with Biebrich Scarlet-Acid Fusion (Sigma-Aldrich, St. Louis, MO), washed, stained with Phosphomolybdic Acid-Phosphotunsctic Acid, and then stained with Aniline Blue (Sigma-Aldrich, St. Louis, MO).

Liver triglycerides

We evaluated the effects of 17α-E2 treatment on triglyceride accumulation in the liver. Liver samples (~100 mg) were homogenized on ice for 60 s in 10X (v/w) Cell Signaling Lysis Buffer (Cell Signaling, Danvers, MA) with protease and phosphatase inhibitors (Boston BioProducts, Boston, MA). Total lipid was extracted from the homogenate using the Folch method with a 2:1 chloroform-methanol mixture (Folch et al., 1957). Lipid was dried down using a nitrogen drier at room temperature, and resuspended in 100 μl of 3:1:1 tert-butyl alcohol-methanol-Triton X-100 solution. Final triglyceride concentrations were determined using a spectrophotometric assay with a 4:1 Free Glycerol Agent/Triglyceride Agent solution (Sigma Triglyceride and Free-Glycerol reagents, St. Louis, MO) as previously described (Stout et al., 2011).

Liver fatty acids

We evaluated the effects of 17α-E2 on hepatic fatty acid content. Liver samples (~50 mg) were homogenized and on ice for 60 s in 10X (v/w) Cell Signaling Lysis Buffer (Cell Signaling, Danvers, MA) with protease and phosphatase inhibitors (Boston BioProducts, Boston, MA). Total lipid was extracted using a modified Bligh and Dyer method (Bligh and Dyer, 1959) (Sigma-Aldrich, St. Louis, MO). Of 15:0 and 17:0 internal standards, 50 nmol were added and acid hydrolysis/methanolysis was done to generate fatty acid methyl esters (FAMEs) (Agbaga et al., 2018). FAMEs were identified as previously described by GC-MS (Agbaga et al., 2018). A 6890N gas chromatograph with flame ionization detector (GC-FID) (Agilent Technologies) was used to quantify FAMEs (Yu et al., 2012). Standards 15:0 and 17:0 were used to compare and determine sample concentrations. Data is represented as the relative mole percent of each fatty acid.

Plasma eicosanoids

We evaluated the effects of 17α-E2 treatment on circulating eicosanoids (Supplementary file 3). Plasma eicosanoid analyses were performed by the UCSD Lipidomics Core as described previously (Quehenberger et al., 2010). Eicosanoids were isolated from plasma, extracted, separated using liquid chromatography, and analyzed with mass spectrometry (MDS SCIEX 4000 Q Trap; Applied Biosystems, Foster City, CA) (Quehenberger et al., 2010).

Real-time PCR

To evaluate alterations in gene expression following 17α-E2 treatment, we performed qPCR for genes related to fibrosis, lipid metabolism, insulin resistance, and glucose metabolism in the liver. Total RNA was extracted using Trizol (Life Technologies, Carlsbad, CA) and was reverse transcribed to cDNA with the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City,
Real-time PCR was performed in a QuantStudio 12K Flex Real Time PCR System (Thermofisher Scientific, Waltham, MA) using TaqMan Gene Expression Master Mix (Applied Biosystems/Thermofisher Scientific, Waltham, MA) and predesigned gene expression assays with FAM probes from Integrated DNA Technologies (Skokie, Illinois). Target gene expression was expressed as $2^{-\Delta\Delta CT}$ by the comparative CT method (Livak and Schmittgen, 2001) and normalized to the expression of TATA-Box Binding Protein (TBP) in liver.

**Western blotting**

To determine if 17α-E2 altered hepatic insulin sensitivity, we evaluated phosphorylation status of AKT and FOXO1 following an insulin bolus. Liver was homogenized in RIPA Buffer (Cell Signaling, Danvers, MA) with protease and phosphatase inhibitors (Boston Bioproducts, Boston, MA). Total protein was quantified using BCA Protein Assay Reagent Kit (Pierce, Rockford, IL). Proteins were separated on an Any kD Criterion TGX Stain-Free Protein Gel (Biorad, Hercules, CA) at 75V for 150 min in Running Buffer (Cell Signaling, Danvers, MA) and transferred to a 0.2 μm pore size nitrocellulose membrane, (Biorad, Hercules, CA) at 75V for 90 min on ice. Primary antibodies used were pS256 FOX01 (Abcam ab131339, 1:1000), FOX01a (Abcam ab52857, 1:1000), pS473 AKT (Abcam ab81283, 1:3000), pan-AKT (Abcam ab179463, 1:10000), GAPDH (Abcam ab9485, 1:2500). Primary antibody detection was performed with IRDye 800CW Infrared Rabbit (LI-COR Biotechnology, Lincoln, NE) at 1:15,000 concentration. GAPDH was diluted in 5% dry milk (Cell Signaling, Danvers, MA), all other antibodies were diluted in 5% BSA (Cell Signaling, Danvers, MA). Blot imaging was done on Odyssey Fc Imaging System (LI-COR Biotechnology, Lincoln, NE) with a two-minute exposure time at 800l, and protein detection and quantification were performed using Image Studio Software (LI-COR Biotechnology, Lincoln, NE).

**Statistical analyses**

Results are presented as mean ± SEM unless otherwise stated with $p$ values less than 0.05 considered to be significant unless otherwise specified. Analyses of differences between groups were performed by two-way ANOVA, two-way repeated measures ANOVA, or Student’s t-test where appropriate using SigmaPlot 12.5 Software. A Benjamini-Hochberg multiple testing correction was applied to the $F$ test result to correct for the number of transcripts, proteins, and fatty acids analyzed.

**Acknowledgements**

We thank Dr. Kenneth Korach at the National Institute of Environmental Health Sciences for providing ERα KO and WT littermate mice. We also thank Dr. Lora Bailey-Downs, Richard Brush, and Michael Sullivan for technical support. This work was supported by the National Institutes of Health (R00 AG51661 and R01 AG069742 to MBS, T32 AG052363 to SNM, R01 EY030513 to M-PA, and R01 AG059430 to WMF), Veterans Affairs (I01BX003906 to WMF) and pilot research funding from the Harold Hamm Diabetes Center (MBS and SNM), Einstein Nathan Shock Center (P30 AG038072) of Excellence in the Basic Biology of Aging (MBS), and OUHSC Lipidomics Core (P30 EY012190).

**Additional information**

**Funding**

| Funder                        | Grant reference number | Author                  |
|-------------------------------|------------------------|-------------------------|
| National Institutes of Health | R00 AG51661            | Michael B Stout         |
| Harold Hamm Diabetes Center   | Pilot Research Funding | Shivani N Mann          |
|                               |                        | Michael B Stout         |
| National Institutes of Health | R01 AG069742           | Michael B Stout         |
| National Institutes of Health | R01 AG059430           | Willard M Freeman       |
| Veterans Affairs Oklahoma City| I01BX003906            | Willard M Freeman       |
| University of Oklahoma Health | P30 EY012190           | Martin-Paul Agbaga      |
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author contributions
Shivani N Mann, Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Writing - original draft, Project administration, Writing - review and editing; Niran Hadad, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - review and editing; Molly Nelson Holte, Formal analysis, Validation, Methodology; Alicia R Rothman, Formal analysis, Validation, Writing - review and editing; Roshini Sathiaseelan, Formal analysis, Investigation, Methodology; Samim Ali Mondal, Formal analysis, Investigation, Writing - review and editing; Martin-Paul Agbaga, Archana Unnikrishnan, Formal analysis, Investigation, Methodology, Writing - review and editing; Malayannan Subramaniam, Formal analysis, Supervision, Investigation, Methodology, Writing - review and editing; John Hawse, Formal analysis, Supervision, Validation, Investigation, Methodology, Writing - review and editing; Derek M Huffman, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - review and editing; Willard M Freeman, Data curation, Software, Formal analysis, Supervision, Investigation, Visualization, Writing - review and editing; Michael B Stout, Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing

Author ORCIDs
Willard M Freeman http://orcid.org/0000-0001-7027-999X
Michael B Stout https://orcid.org/0000-0002-9996-9123

Ethics
Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#19-063-SEAHi) of the University of Oklahoma Health Science Center.

Decision letter and Author response
Decision letter https://doi.org/10.7554/eLife.59616.sa1
Author response https://doi.org/10.7554/eLife.59616.sa2

Additional files
Supplementary files
- Supplementary file 1. Pairwise statistical comparisons of ERα binding. Negative binomial regression Wald post-hoc comparison test, FDR < 0.05. n = 3/group.
- Supplementary file 2. ERα binding motif analysis. Motif analysis was performed using HOMER with standard settings with the significance threshold set to FDR corrected p<0.05. Peak regions called for each treatment group were analyzed to identify enriched motifs relative to the entire genome. Hypergeometric test was used to test enrichment. Only motifs with FDR corrected p<0.05 were reported as significant. For pairwise differential motif enrichment or depletion across experimental groups, we utilized the hypergeometric test by using the number of sequences with motif from each group and total number of peaks as total sample size. Motifs that appear in less than five sequences between both test groups were removed. Benjamini-Hochberg multiple testing correction was utilized to control for false discovery rate (FDR < 0.05).
Supplementary file 3. Circulating eicosanoid levels (pmol/ml). 17α-E2 mildly alters the circulating eicosanoid profile in obese middle-aged male mice. WT mice were provided 45% HFD (TestDiet 58V8):17α-E2 (14.4ppm) for 14 weeks. Age-matched, male WT, chow-fed (TestDiet 58YP) mice were also evaluated as a normal-weight reference group. All data are presented as mean ± SEM and were analyzed by Student’s t-test with the WT Chow group being excluded from statistical comparisons. n = 5–7.

Transparent reporting form

Data availability
Sequencing data has been deposited in GEO under accession code GSE151039.

The following dataset was generated:

| Author(s)       | Year | Dataset title                                                                 | Dataset URL                                      | Database and Identifier |
|-----------------|------|------------------------------------------------------------------------------|-------------------------------------------------|-------------------------|
| Stout M, Hawse J, Freeman W, Hadad N, Mann S | 2020 | Assessment of transcriptional ERα activity following exposure to 17α-E2 and 17β-E2 | https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE151039 | NCBI Gene Expression Omnibus, GSE151039 |

References

Acosta-Martinez M, Horton T, Levine JE. 2007. Estrogen receptors in neuropeptide Y neurons: at the crossroads of feeding and reproduction. Trends in Endocrinology & Metabolism 18:48–50. DOI: https://doi.org/10.1016/j.tem.2006.12.001, PMID: 17174101

Aighba MP, Merriman DK, Brush RS, Lydic TA, Conley SM, Naash MI, Jackson S, Woods AS, Reid GE, Busik JV, Anderson RE. 2018. Differential composition of DHA and very-long-chain PUFAs in rod and cone photoreceptors. Journal of Lipid Research 59:1586–1596. DOI: https://doi.org/10.1194/jlr.M082495, PMID: 29986998

Allard C, Morford JJ, Xu B, Salwen B, Xu W, Desmoulins L, Zsombok A, Kim JK, Levin ER, Mauvais-Jarvis F. 2019. Loss of nuclear and membrane estrogen Receptor-α differentially impairs insulin secretion and action in male and female mice. Diabetes 68:490–501. DOI: https://doi.org/10.2337/db18-0293, PMID: 30305367

Anstead GM, Carlson KE, Katzenellenbogen JA. 1997. The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 62:268–303. DOI: https://doi.org/10.1006/s0039-128X(96)00242-5, PMID: 9071738

Ayala JE, Samuel VT, Morton GJ, Obici S, Croniger CM, Shulman GI, Wasserman DH, McGuinness OP, NIH Mouse Metabolic Phenotyping Center Consortium. 2010. Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. Disease Models & Mechanisms 3:525–534. DOI: https://doi.org/10.1242/dmm.006239, PMID: 20713647

Banner KH, Leung H, Phillips KM, Lin Y, Yeh R, Vogel J, Wang X, Eisenberg S, He Y, Zhang J, Elmore SR. 2014. The effects of 17β-estradiol on adiposity-related gene expression in male and female mice. Obesity 22:1339–1349. DOI: https://doi.org/10.1002/oby.20541, PMID: 24942239

Bischof GN, Benedusi V, Martini E, Kallikourdis M, Villa A, Meda C, Maggi A. 2015. Ovariectomy shortens the life span of female mice. Oncotarget 6:10801–10811. DOI: https://doi.org/10.18632/oncotarget.2984, PMID: 25719423

Bischof GN, Park DC. 2015. Obesity and aging: consequences for cognition, brain structure, and brain function. Psychosomatic Medicine 77:697–709. DOI: https://doi.org/10.1097/PSY.0000000000000212, PMID: 26107577

Bligh EG, Dyer WJ. 1959. A rapid method of total lipid extraction and purification. Canadian Journal of Biochemistry and Physiology 37:911–917. DOI: https://doi.org/10.1139/o59-099, PMID: 13671370

Bolduc C, Larose M, Yoshioka M, Ye P, Belbeau P, Labrie C, Morissette J, Raymond V, Labrie F, St-Amand J. 2004. Effects of dihydrotestosterone on adipose tissue measured by serial analysis of gene expression. Journal of Molecular Endocrinology 33:429–444. DOI: https://doi.org/10.1677/jme.0.101503, PMID: 15525599

Brandt C, Nolte H, Henschke S, Engström Ruud L, Awazawa M, Morgan DA, Gabel P, Sprenger HG, Hess ME, Günther S, Langer T, Rahmoni K, Fenselau H, Krüger M, Brüning JC. 2018. Food perception primes hepatic ER homeostasis via Melanocortin-Dependent control of mTOR activation. Cell 175:1321–1335. DOI: https://doi.org/10.1016/j.cell.2018.02.028, PMID: 29450745

Brussaard HE, Gevers Leuven JA, Frölich M, Kluft C, Krens HM. 1997. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia 40:843–849. DOI: https://doi.org/10.1007/s001250050738, PMID: 9243107

Camporez JP, Jornayvaz FR, Lee HY, Kanda S, Guigni BA, Kahn M, Samuel VT, Carvalho CR, Petersen KF, Jurczak MJ, Shulman GI. 2013. Cellular mechanism by which oestradiol protects female ovariectomized mice from high-fat diet-induced hepatic and muscle insulin resistance. Endocrinology 154:1021–1028. DOI: https://doi.org/10.1210/en.2012-1989, PMID: 23364948
Cherrington AD, Wasserman DH, McGinness OP. 1994. Renal contribution to glucose production after a brief fast: fact or fancy? The Journal of Clinical Investigation 93:2303. DOI: https://doi.org/10.1172/JCI117232, PMID: 8200961

Crary GS, Albrecht JH. 1998. Expression of cyclin-dependent kinase inhibitor p21 in human liver. Hepatology 28:738–743. DOI: https://doi.org/10.1002/hep.510280320, PMID: 9731566

D’Amato NC, Gordon MA, Babbs B, Spoelstra NS, Carson Butterfield KT, Torkko KC, Phan VT, Barton VN, Rogers TJ, Sartorius CA, Elias A, Gertz J, Jacobsen BM, Richer JK. 2016. Cooperative dynamics of AR and ER activity in breast Cancer. Molecular Cancer Research : MCR 14:1054–1067. DOI: https://doi.org/10.1158/1541-7786.MCR-16-0167, PMID: 27565181

Debarba LK. 2020. Sex hormones underlying 17α-estradiol effects on neuroinflammation. bioRxiv. DOI: https://doi.org/10.1101/2020.05.26.117689

Della Torre S, Mitro N, Fontana R, Gomaraschi M, Favari E, Recordati C, Lolli F, Quagliarini F, Meda C, Ohsloin C, Crestani M, Uhlenhaut NH, Calabresi L, Maggi A. 2016. An essential role for liver er and coupling hepatic metabolism to the reproductive cycle. Cell Reports 15:360–371. DOI: https://doi.org/10.1016/j.celrep.2016.03.019, PMID: 27050513

Dirks AJ, Leeuwenburgh C. 2006. Caloric restriction in humans: potential pitfalls and health concerns. Mechanisms of Ageing and Development 127:1–7. DOI: https://doi.org/10.1016/j.mad.2005.09.001, PMID: 16226298

Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. 2013. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29:15–21. DOI: https://doi.org/10.1093/bioinformatics/bts635, PMID: 23104885

Dodd GT, Michael NJ, Lee-Young RS, Mangiapico SP, Pyyro JT, Munder AC, Simonds SE, Brüning JC, Zhang ZY, Cowley MA, Andrikopoulos S, Horvath TL, Spanswick D, Tiganis T. 2018. Insulin regulates POMC neuronal plasticity to control glucose metabolism. eLife 7:e38704. DOI: https://doi.org/10.7554/elife.38704, PMID: 30230471

Downman JK, Hopkins LJ, Reynolds GM, Armstrong MJ, Nasiri M, Nikolau N, van Houten EL, Visser JA, Morgan SA, Lavery GG, Oprescu A, Hübscher SG, Newsome PN, Tomlinson JW. 2013. Loss of 5α-reductase type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice. Endocrinology 154:4536–4547. DOI: https://doi.org/10.1210/en.2013-1592, PMID: 24080367

Dye L, Boyle NB, Champ C, Lawton C. 2017. The relationship between obesity and cognitive health and decline. The Proceedings of the Nutrition Society 76:443–454. DOI: https://doi.org/10.1017/S0029665117002014, PMID: 28889622

Edwards DP, McGuire WL. 1980. 17α-estradiol is a biologically active estrogen in human breast Cancer cells in tissue culture*. Endocrinology 107:884–891. DOI: https://doi.org/10.1210/endo-107-4-884

Einstein FH, Huffman DM, Fishman S, Jerschow E, Heo HJ, Atzmon G, Schechter C, Barzilai N, Muzumdar RH. 2010. Aging per se increases the susceptibility to free fatty Acid-Induced insulin resistance. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 65A:800–808. DOI: https://doi.org/10.1093/gerona/gloq078

Engler-Chiurazzi EB, Covey DF, Simpkins JW. 2017. A novel mechanism of non-feminizing estrogens in neuroprotection. Experimental Gerontology 94:99–102. DOI: https://doi.org/10.1016/j.exger.2016.10.013, PMID: 27818250

Flegal KM, Carroll MD, Ogden CL, Curtin LR. 2010. Prevalence and trends in obesity among US adults, 1999-2008. Jama 303:235–241. DOI: https://doi.org/10.1001/jama.2009.2004, PMID: 20071471

Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. 2016. Trends in obesity among adults in the united states, 2005 to 2014. Jama 315:2284–2291. DOI: https://doi.org/10.1001/jama.2016.6458, PMID: 27272580

Flouriot G, Griffin C, Kenealy M, Sonntag-Buck V, Gannon F. 1998. Differentially expressed messenger RNA isoforms of the human estrogen receptor-alpha gene are generated by alternative splicing and promoter usage. Molecular Endocrinology 12:1939–1954. DOI: https://doi.org/10.1210/mend.12.12.0209, PMID: 9849967

Folch J, Lees M, Sloane Stanley GH. 1957. A simple method for the isolation and purification of total lipides from animal tissues. The Journal of Biological Chemistry 226:497–509. PMID: 13428781

Garratt M, Bower B, Garcia GG, Miller RA. 2017. Sex differences in lifespan extension with acarbose and 17α estradiol: gonadal hormones underlie male-specific improvements in glucose tolerance and mTORC2 signaling. Aging Cell 16:1256–1266. DOI: https://doi.org/10.1111/ace1.12656, PMID: 28834262

Garratt M, Lagerborg KA, Tsai YM, Galecki A, Jain M, Miller RA. 2018. Male lifespan extension with 17α estradiol is linked to a sex-specific metabolic response modulated by gonadal hormones in mice. Aging Cell 17:e12786. DOI: https://doi.org/10.1111/ace1.12786, PMID: 29806096

Garratt M, Stout MB. 2018. Hormone actions controlling sex-specific life-extension. Aging 10:293–294. DOI: https://doi.org/10.18632/aging.101396, PMID: 29514132

GBD 2017 Cirrhosis Collaborators, Collaborators G. 2020. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. The Lancet. Gastroenterology & Hepatology 5:245–266. DOI: https://doi.org/10.1016/S2468-1253(19)30349-8, PMID: 31981519

Gilroy DW, Edin ML, De Maeyer RP, Bystrom J, Newson J, Lih FB, Stables M, Zeldin DC, Bishop-Bailey D. 2016. CYP450-derived oxylipins mediate inflammatory resolution. PNAS 113:E3240–E3249. DOI: https://doi.org/10.1073/pnas.1521453113, PMID: 27226306
Glass O, Henao R, Patel K, Guy CD, Gruss HJ, Syn WK, Moylan CA, Streilein R, Hall R, Mae Diehl A, Abellamek MF. 2018. Serum interleukin-8, osteopontin, and monocyte chemoattractant protein-1 are associated with hepatic fibrosis in patients with nonalcoholic fatty liver disease. Hepatology Communications 2:1344–1355. DOI: https://doi.org/10.1002/hepc.21344, PMID: 30411081

Gould ML, Hurst PR, Nicholson HD. 2007. The effects of oestrogen receptors alpha and beta on testicular cell number and steroidogenesis in mice. Reproduction 134:271–279. DOI: https://doi.org/10.1530/REP-07-0025, PMID: 17660237

Grattaglione I, Montezinho LP, Oliveira PJ, Frühbeck G, Gómez-Ambrosi J, Montecucco F, Carbone F, Wieckowski MR, Wang DQ, Portincasa P. 2019. Targeting mitochondria to oppose the progression of nonalcoholic fatty liver disease. Biochemical Pharmacology 160:34–45. DOI: https://doi.org/10.1016/j.bcp.2018.11.020, PMID: 30508523

Green PS, Simpkins JW. 2000. Estrogens and estrogen-like non-feminizing compounds play a role in the prevention and treatment of Alzheimer’s disease. Annals of the New York Academy of Sciences 924:93–98. DOI: https://doi.org/10.1111/j.1749-6632.2000.tb05566.x, PMID: 11193809

Guillaume M, Riant E, Fabre A, Raymond-Letron I, Buscato M, Davezac M, Tramunt B, Montagner A, Smati S, Zahreddine R, Paliere G, Valera MC, Guillou H, Lenfant F, Unsicker K, Metivier R, Fontaine C, Arnal JF, Gourdy P. 2019. Selective liver estrogen receptor α modulation prevents steatosis, Diabetes, and Obesity Through the Anorectic Growth Differentiation Factor 15 Hepatome in Mice. Hepatology Communications 3:908–924. DOI: https://doi.org/10.1002/hep4.1363, PMID: 31304450

Gray J, Peters MG. 2013. Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes. Gastroenterology 145:633–639.

Hadad N, Masser DR, Blanco-Berdugo L, Stanford DR, Freeman WM. 2019. Early-life DNA methylation profiles are indicative of age-related transcriptome changes. Epigenetics & Chromatin 12:58. DOI: https://doi.org/10.1186/s13072-019-0306-5, PMID: 31594536

Harrison DE, Strong R, Allison DB, Ames BN, Astle CM, Atamna H, Fernandez E, Flurkey K, Javors MA, Nadon NL, Nelson JF, Pletcher S, Simpkins JW, Smith D, Wilkinson JE, Miller RA. 2014. Acarbose, 17-α-estradiol, and norhydrogudiaicatic acid extend mouse lifespan preferentially in males. Aging Cell 13:273–282. DOI: https://doi.org/10.1111/acel.12170, PMID: 24245655

Hayashi M, Nomoto S, Hishida M, Inokawa Y, Kanda M, Okamura Y, Nishikawa Y, Tanaka C, Kobayashi D, Yamada S, Nakayama G, Fujii T, Sugimoto H, Koike M, Fujiwara M, Takeda S, Kodera Y. 2014. Identification of the collagen type 1 α1 gene (COL1A1) as a candidate survival-related factor associated with hepatocellular carcinoma. BMC Cancer 14:108. DOI: https://doi.org/10.1186/1471-2407-14-108, PMID: 24552139

Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS. 2000. Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. PNAS 97:12729–12734. DOI: https://doi.org/10.1073/pnas.97.23.12729, PMID: 11070086

Horvath S, Erhart W, Bross H, Ammerpohl O, von Schönfels W, Ahrens M, Heits N, Takaoka S, Kudo E, Yamauchi T. 2014. Identification of the collagen type 1 α1 gene (COL1A1) as a candidate survival-related factor associated with hepatocellular carcinoma. BMC Cancer 14:108. DOI: https://doi.org/10.1186/1471-2407-14-108, PMID: 24552139

Huffaker DM, Farias Quipildor G, Mao K, Zhang X, Wan J, Apontes P, Cohen P, Barzilai N. 2016a. Central insulin-like growth factor-1 (IGF-1) restores whole-body insulin action in a model of age-related insulin resistance and IGF-1 decline. Aging Cell 15:181–186. DOI: https://doi.org/10.1111/acel.12415, PMID: 26534869

Huffman DM, Justice JN, Stout MB, Kirkland JL, Barzilai N, Austad SN. 2016b. Evaluating health span in preclinical models of aging and disease: guidelines, challenges, and opportunities for geroscience. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 71:1395–1406. DOI: https://doi.org/10.1093/gerona/glw106

Hunt NJ, Kang SWS, Lockwood GP, Le Couteur DG, Cogger VC. 2019. Hallmarks of aging in the liver. Computational and Structural Biotechnology Journal 17:1151–1161. DOI: https://doi.org/10.1002/csbi.2019.07.021, PMID: 31462971

Iñigo MR, Amorese AJ, Tarpey MD, Balestrieri NP, Jones KG, Patteson DJ, Jackson KC, Torres MJ, Lin CT, Smith CD, Heden TD, McMillin SL, Weyrauch LA, Stanley EC, Schmidt CA, Kilburg-Basnyat BB, Reece SW, Psaltis CE, McMillin SL, Sung J, Lincoln B, Jordan HS, et al. 2014. AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American college of cardiology/American heart association task force on practice guidelines and the obesity society. Circulation 129:S102–S138. DOI: https://doi.org/10.1161/CIR.0000437739.71477.ee, PMID: 2422017

Kaur SP, Bansal S, Chopra K. 2015. 17α-estradiol: a candidate neuroserm and non-feminizing estrogen for postmenopausal neuronal complications. Steroids 86:1–5. DOI: https://doi.org/10.1016/j.steroids.2015.01.004, PMID: 25595449

Kelly MJ, Ronneklev OK. 2015. Minireview: neural signaling of estradiol in the hypothalamus. Molecular Endocrinology 29:645–657. DOI: https://doi.org/10.1210/me.2014-1397, PMID: 25751314
Khosla S, Monroe DG. 2018. Regulation of bone metabolism by sex steroids. Cold Spring Harbor Perspectives in Medicine 8:a031211. DOI: https://doi.org/10.1101/cshperspect.a031211, PMID: 28710257

Kim IH, Kisseleva T, Brenner DA. 2015. Aging and liver disease. Current Opinion in Gastroenterology 31:184–191. DOI: https://doi.org/10.1097/MOG.0000000000000176, PMID: 25850346

Kiss L, Schütte H, Padberg W, Weissmann N, Mayer K, Gessler T, Voswinckel R, Seeger W, Grimminger F. 2010. Epoxycatstatrinoids are the dominant eicosanoids in human lungs upon microbial challenge. European Respiratory Journal 36:1083–1098. DOI: https://doi.org/10.1183/09031936.000393.93, PMID: 20378604

Kohli P, Levy BD. 2009. Resolvin and protectins: mediating solutions to inflammation. British Journal of Pharmacology 158:960–971. DOI: https://doi.org/10.1111/j.1476-5381.2009.00290.x, PMID: 19594757

Könniger AC, Janoschek R, Plum L, Jordan SD, Rother E, Ma X, Xu C, Enniori P, Hampel B, Barsh GS, Kahn CR, Cowley MA, Ashcroft FM, Brüning JC. 2007. Insulin action in AgRP-expressing neurons is required for suppression of hepatic glucose production. Cell Metabolism 5:438–449. DOI: https://doi.org/10.1016/j.cmet.2007.05.004, PMID: 17550779

Koo BK, Um SH, Seo DS, Joo SK, Bae JM, Park JH, Chang MS, Kim JH, Lee J, Jeong WJ, Kim W. 2018. Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease. Liver International 38:695–705. DOI: https://doi.org/10.1111/liv.13587, PMID: 28898507

Korenman SG. 1969. Comparative binding affinity of estrogens and its relation to estrogenic potency. Steroids 13:163–177. DOI: https://doi.org/10.1016/0039-128X(69)90004-X, PMID: 5773887

Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with bowtie 2. Nature Methods 9:357–359. DOI: https://doi.org/10.1038/nmeth.1923, PMID: 22388286

Lee SK, Choi HS, Song MR, Lee MO, Lee JW. 1998. Estrogen receptor, a common interaction partner for a subset of nuclear receptors. Molecular Endocrinology 12:1184–1192. DOI: https://doi.org/10.1210/mend.12.8.0146, PMID: 9717844

Leonard AK, Loughran EA, Klymenko Y, Liu Y, Kim O, Asem M, McCabee K, Ravosa MJ, Stack MS. 2018. Methods for the visualization and analysis of extracellular matrix protein structure and degradation. Methods in Cell Biology 143:79–95. DOI: https://doi.org/10.1016/bs.mcb.2017.08.005, PMID: 29310793

Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, 1000 Genome Project Data Processing Subgroup. 2009. The sequence alignment/Map format and SAMtools. Bioinformatics 25:2078–2079. DOI: https://doi.org/10.1093/bioinformatics/btp352, PMID: 19505943

Lichtinghagen R, Bahr MJ, Wehmeier M, Michelsd L, Haberkorn CI, Arndt B, Fleming P, Manns MP, Boeker KHW. 2003. Expression and coordinated modulation of matrix metalloproteinases in chronic hepatitis C and KHHV. Clinical Science 105:373–382. DOI: https://doi.org/10.1042/CS20030098

Lin CY, Vega VB, Thomsen JS, Zhang T, Kong SL, Xie M, Chiu KP, Lipovich L, Barnett DH, Stossi F, Yeo A, George J, Kuznetsov VA, Lee YK, Charn TH, Palanisamy N, Miller LD, Cheung E, Katzenellenbogen BS, Ruan Y, et al. 2007. Whole-genome cartography of estrogen receptor alpha binding sites. PLOS Genetics 3:e87. DOI: https://doi.org/10.1371/journal.pgen.0030087, PMID: 17542468

Lin AH, Li RW, Ho EY, Leung GP, Leung SW, Vanhoutte PM, Man RY. 2013. Differential ligand binding affinities of human estrogen Receptor-a isoforms. PLOS ONE 8:e63199. DOI: https://doi.org/10.1371/journal.pone.0063199, PMID: 23646196

Littlefield BA, Gurpide E, Markiewicz L, McKinley B, Hochberg RB. 1990. A simple and sensitive microtiter plate estrogen bioassay based on stimulation of alkaline phosphatase in Ishikawa cells: estrogenic action of Delta 5adrenal steroids. Endocrinology 127:2757–2762. DOI: https://doi.org/10.1210/endo-127-6-2757, PMID: 2249627

Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2-Delta Delta (C(T)) Method. Methods 25:402–408. DOI: https://doi.org/10.1006/meth.2001.1262, PMID: 11846609

Livingstone DE, Barat P, Di Rollo EM, Rees GA, Weldin BA, Rog-Zielinska EA, MacFarlane DP, Walker BR, Andrew R. 2015. Srx-Reductase type 1 deficiency or inhibition predisposes to insulin resistance, hepatic Steatosis, and liver fibrosis in rodents. Diabetes 64:447–458. DOI: https://doi.org/10.2337/db14-0249, PMID: 25239636

López M, Tena-Sempere M. 2015. Estrogens and the control of energy homeostasis: a brain perspective. Trends in Endocrinology & Metabolism 26:411–421. DOI: https://doi.org/10.1016/j.tem.2015.06.003, PMID: 26126705

López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. 2013. The hallmarks of aging. Cell 153:1194–1217. DOI: https://doi.org/10.1016/j.cell.2013.05.039, PMID: 23746838

Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biology 15:550. DOI: https://doi.org/10.1186/s13059-014-0550-8, PMID: 25516281

Lu M, Wan M, Leavens KF, Chu Q, Monks BR, Fernandez S, Ahima RS, Ueki K, Kahn CR, Birnbaum MJ. 2012. Insulin regulates liver metabolism in vivo in the absence of hepatic akt and Foxo1. Nature Medicine 18:388–395. DOI: https://doi.org/10.1038/nn.2686, PMID: 22344295

Luu J, Li Y, Zagyria JA, Wang KS, French SW, Sévigny J, Asahina K. 2016. Characterization of hepatic stellate cells, portal fibroblasts, and mesothelial cells in normal and fibrotic livers. Journal of Hepatology 64:1137–1146. DOI: https://doi.org/10.1016/j.jhep.2016.01.010, PMID: 26806818

Madala SK, Pesce JT, Ramalingam TR, Wilson MS, Minnicozzi S, Cheever AW, Thompson RW, Mentink-Kane MM, Wynn TA. 2010. Matrix metalloproteinase 12-deficiency augments extracellular matrix degrading metalloproteinases and attenuates IL-13-dependent fibrosis. The Journal of Immunology 184:3955–3963. DOI: https://doi.org/10.4049/jimmunol.0903008, PMID: 20181883
et al. 2020. Short-term calorie restriction and 17α-estradiol administration elicit divergent effects on proteostatic processes and protein content in metabolically active tissues. The Journal of Gerontology: Series A 75: 849–857. DOI: https://doi.org/10.1093/gerona/glz113

Mann SN, Pitel KS, Nelson-Holte MH, Iwaniec UT, Turner RT, Sathiaeseelan R, Kirkland JL, Schneider A, Morris KT, Malayannan S, Hawse JR, Stout MB. 2020. 17α-estradiol prevents ovariectomy-mediated obesity and bone loss. Experimental Gerontology 142:111113. DOI: https://doi.org/10.1016/j.exger.2020.111113, PMID: 33065227

Mannrique C, Lastra G, Habibi J, Mugerfeld I, Garro M, Sowers JR. 2012. Loss of estrogen receptor α signaling leads to insulin resistance and obesity in adult and female mice. Cardiorenal Medicine 2:200–210. DOI: https://doi.org/10.1007/s00335-012-9430-2, PMID: 22969776

Meda C, Barone M, Mitro N, Lollif F, Pedretti S, Caruso D, Maggi A, Della Torre S. 2020. Hepatic sex accounts for sex differences in the ability to cope with an excess of dietary lipids. Molecular Metabolism 32:97–108. DOI: https://https://doi.org/10.1016/j.molmet.2019.12.009, PMID: 32029233

Miller BF. 2020. Short-term calorie restriction and 17α-estradiol administration elicit divergent effects on proteostatic processes and protein content in metabolically active tissues. The Journal of Gerontology: Series A 75: 849–857. DOI: https://doi.org/10.1093/gerona/glz113

Monroe DG, Getz BJ, Johnsen SA, Riggs BL, Khosla S, Spelsberg TC. 2003. Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERα or ERβ. Journal of Cellular Biochemistry 90:315–326. DOI: https://doi.org/10.1002/jcb.10633, PMID: 14505348

Monroe DG, Secreto FJ, Subramaniam M, Getz BJ, Khosla S, Spelsberg TC. 2005. Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. Molecular Endocrinology 19:1555–1568. DOI: https://doi.org/10.1210/me.2004-0381, PMID: 15802376

Méndez E, Skrtic S, Venken K, Andersson N, Lindberg MK, Svensson J, Swanson C, Vanderschueren D, Oscarsson J, Gustafsson JA, Ohlsson C. 2006. Dihydrotestosterone treatment results in obesity and altered lipid metabolism in orchidectomized mice. Obesity 14:662–672. DOI: https://journals.lww.com/oby/doi/10.1038/oby.2006.75, PMID: 16741268

Murray SA, Eppig JT, Smedley D, Simpson EM, Rosenthal N. 2012. Beyond knockouts: CRE resources for conditional mutagenesis. Mammalian Genome 23:587–599. DOI: https://doi.org/10.1007/s00335-012-9430-2, PMID: 22962623

Nelson JD, Denisenko O, Sova P, Bomsztyk K. 2006. Fast chromat immunoprecipitation assay. Nucleic Acids Research 34:e2. DOI: https://doi.org/10.1093/nar/gnj004, PMID: 16397291

Nevalainen T, Kananen L, Marttila S, Jylhävää J, Mononen N, Kähönén M, Raitakari OT, Hervonen A, Jylhä M, Lehtimäki T, Hurme M. 2017. Obesity accelerates epigenetic aging in middle-aged but not in elderly individuals. Clinical Epigenetics 9:20. DOI: https://doi.org/10.1186/s13886-016-0301-7, PMID: 28289477

Ogrodnik M, Miwa S, Tchkonia T, Tiniakos D, Wilson CL, Lahat A, Day CP, Burt A, Palmer A, Anstee QM, Grellscheid SN, Hoeijmakers JHJ, Barnhoorn S, Mann DA, Bird TG, Vermeij WP, Kirkland JL, Passos JF, von Zglinicki T, Jurk D. 2017. Cellular senescence drives age-dependent hepatic steatosis. Nature Communications 8:15691. DOI: https://doi.org/10.1038/s41467-017-01937-4, PMID: 28608850

Orfano CE, Vogels L. 1980. [Local therapy of androgenetic alopecia with 17 alpha-estradiol A controlled, randomized double-blind study (author's transl).] Dermatologica 161:124–132. PMID: 7398983

Panet-Raymond V, Gottlieb B, Beitel KL, Pinsky L, Trífiro MA. 2000. Interactions between androgen and estrogen receptors and the effects on their transactivation properties. Molecular and Cellular Endocrinology 167:139–150. DOI: https://doi.org/10.1016/S0303-7207(00)00279-3, PMID: 11000528

Parks BW, Sallam T, Mehrabian M, Psychogios N, Hui ST, Norhjem F, Castellani LW, Rau CD, Pan C, Phun J, Zhou Z, Yang WP, Neuhaus I, Gargalovic PS, Kirchgessner TG, Graham M, Lee R, Tontonoz P, Gerszten RE, Hevener AL, et al. 2015. Genetic architecture of insulin resistance in the mouse. Cell Metabolism 21:334–347. DOI: https://doi.org/10.1016/j.cmet.2015.01.002, PMID: 25651185

Pedram A, Razandi M, Blumberg B, Levin ER. 2016. Membrane and nuclear estrogen receptor α collaborate to suppress adipogenesis but not triglyceride content. The FASEB Journal 30:230–240. DOI: https://doi.org/10.1096/fj.15-274878, PMID: 26373802

Pérez LM, Pareja-Galeano H, Sanchis-Gomar F, Emanuele E, Lucia A, Gálvez BG. 2016. ‘Adipaging’: ageing and obesity share biological hallmarks related to a dysfunctional adipose tissue. The Journal of Physiology 594:3187–3207. DOI: https://doi.org/10.1113/JP271691, PMID: 26926488

Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, Jindal S, Segara D, Jia L, Moore NL, Henshall SM, Birrell SN, Coetzee GA, Sutherland RL, Butler LM, Tilley WD. 2009. Androgen for regulation of gluconeogenesis and lipid metabolism in males. Scientific Reports 7:661. DOI: https://doi.org/10.1038/s41598-017-01937-4, PMID: 28490809

Quenebey, Roger AM, Armando AM, Brown AH, Milne SB, Myers DS, Merrill AH, Bandyopadhyay S, Jones KN, Kelly S, Shaner RL, Sullards CM, Wang E, Murphy RC, Barkley RM, Leiker TJ, Raetz CR, Guan Z, Laird GM, Six DA,
Russell DW, et al. 2010. Lipidomics reveals a remarkable diversity of lipids in human plasma. Journal of Lipid Research 51:3299–3305. DOI: https://doi.org/10.1194/jr.M009449, PMID: 20671299

Reese JM, Brunsma ES, Nelson AW, Chernukhin I, Carroll JS, Li Y, Subramaniam M, Suman VJ, Negron V, Monroe DG, Ingle JN, Goetz MP, Hawse JR. 2018. ERβ-mediated induction of cystatins results in suppression of IGF1 signaling and inhibition of triple-negative breast Cancer metastasis. PNAS 115:E9580–E9589. DOI: https://doi.org/10.1073/pnas.1807751115, PMID: 30257941

Rosenfeld CS, Ganjam VK, Taylor JA, Yuan X, Stiehr JR, Hardy MP, Lubahn DB. 1998. Transcript and translation of estrogen receptor-beta in the male reproductive tract of estrogen receptor-alpha knock-out and wild-type mice. Endocrinology 139:2982–2987. DOI: https://doi.org/10.1210/endo.139.6.6028, PMID: 9607809

Ross-Innes CS, Stark R, Teschedorff AE, Holmes KA, Ali HR, Dunning MJ, Brown GD, Gojis O, Ellis IO, Green AR, Ali S, Chin SF, Palmieri C, Caldas C, Carroll JS. 2012. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481:389–393. DOI: https://doi.org/10.1038/nature10730, PMID: 22217937

Rossi R, OrigiGnani G, Modena MG. 2004. Transdermal 17-beta-estradiol and risk of developing type 2 diabetes in a population of healthy, nonobese postmenopausal women. Diabetes Care 27:645–649. DOI: https://doi.org/10.2337/diabetes.27.3.645, PMID: 14988279

Rubinow KB. 2017. Estrogens and body weight regulation in men. Advances in Experimental Medicine and Biology 1043:285–313. DOI: https://doi.org/10.1007/978-3-319-70178-3_14, PMID: 29224100

Ruud J, Steculorum SM, Brünning J. 2017. Neuronal control of peripheral insulin sensitivity and glucose metabolism. Nature Communications 8:15259. DOI: https://doi.org/10.1038/ncomms15259, PMID: 28469281

Salvestrini V, Sell C, LorenzoN A. 2019. Obesity may accelerate the aging process. Frontiers in Endocrinology 10:266. DOI: https://doi.org/10.3389/fendo.2019.00266, PMID: 31130916

Sánchez-Criado JE, Trudgen K, Millán Y, Blanco A, Monterde J, Garrido-Gracia JC, Gordon A, Aguilar R, de Las Mulas JM, Ko C. 2012. Estrogen receptor (ESR1) 2 partially offsets the absence of ESR1 in gonadotropes of pituitary-specific Esr1 knockout female mice. Reproduction 143:549–558. DOI: https://doi.org/10.1530/REP-11-0214, PMID: 22367588

Sar M, Sahu A, Crowley WR, Kalra SP. 1990. Localization of neuropeptide-Y immunoreactivity in estradiol-concentrating cells in the hypothalamus. Endocrinology 127:2752–2756. DOI: https://doi.org/10.1210/endo-127-6-2752, PMID: 2249662

Schriefers H, Wright MC, Rozman T, Hevert F. 1991. Inhibition of testosterone metabolism by 17-alpha-estradiol in rat liver slices. Arzneimittel-Forschung 41:1186–1189. PMID: 1810267

Siddhom S, Schneider A, Fang Y, McFadden S, Darcy J, Sathiaseelan R, Palmer AK, Steyn FJ, Grilli L, Kopchick JJ, Bartke A, Siddiqi S, Masternak MM, Stout MB. 2020. 17α-estradiol modulates IGF1 and hepatic gene expression in a Sex-Specific manner. The Journals of Gerontology: Series A 28:glaa215. DOI: https://doi.org/10.1093/gerona/glaa215

 Skinner DC, Herbison AE. 1997. Effects of photoperiod on estrogen receptor, tyrosine hydroxylase, neuropeptide Y, and beta-endorphin immunoreactivity in the ewe hypothalamus. Endocrinology 138:2585–2595. DOI: https://doi.org/10.1210/endo.138.6.5208, PMID: 9165052

Smith AW, Bosch MA, Wagner EJ, Ranneklev OK, Kelly MJ. 2013. The membrane estrogen receptor ligand STX rapidly enhances GABAergic signaling in NPY/AgRP neurons: role in mediating the anorexigenic effects of 17β-estradiol. American Journal of Physiology-Endocrinology and Metabolism 305:E632–E640. DOI: https://doi.org/10.1152/ajpendo.00281.2013, PMID: 23820624

Smith AW, Ranneklev OK, Kelly MJ. 2014. Gq-ER signaling has opposite effects on hypothalamic orexigenic and anorexigenic neurons. Steroids 81:31–35. DOI: https://doi.org/10.1016/j.steroids.2013.11.007, PMID: 24269736

Stefanska A, Bergmann K, Sypniewska G. 2015. Metabolic syndrome and menopause: pathophysiology, clinical and diagnostic significance. Advances in Clinical Chemistry 72:1–75. DOI: https://doi.org/10.1016/bs.acc.2015.07.001, PMID: 26471080

Steyn FJ, Ngo ST, Chen VP, Bailey-Downs LC, Xie TY, Ghadami M, Brimijoin S, Freeman WM, Rubinstein M, Low MJ, Stout MB. 2018. 17α-estradiol acts through hypothalamic pro-opiomelanocortin expressing neurons to reduce feeding behavior. Aging Cell 17:e12703. DOI: https://doi.org/10.1111/acel.12703

Stincic TL, Ranneklev OK, Kelly MJ. 2018. Diverse actions of estradiol on anorexigenic and orexigenic hypothalamic arcuate neurons. Hormones and Behavior 104:146–155. DOI: https://doi.org/10.1016/j.yhbeh.2018.04.001, PMID: 29626486

Stout MB, Liu LF, Belury MA. 2011. Hepatic steatosis by dietary-conjugated linoleic acid is accompanied by accumulation of diacylglycerol and increased membrane-associated protein kinase C γ in mice. Molecular Nutrition & Food Research 55:1010–1017. DOI: https://doi.org/10.1002/mnfr.201000413, PMID: 21840517

Stout MB, Justice JN, Nicklas BJ, Kirkland JL. 2017a. Physiological aging: links among adipose tissue dysfunction, Diabetes, and Frailty. Physiology 32:9–19. DOI: https://doi.org/10.1530/physiol.0.0012.2016, PMID: 27927801

Stout MB, Steyn FJ, Jurczak MJ, Camporez J-PG, Zhu Y, Hawse JR, Jurk D, Palmer AK, Xu M, Pirskhalava T, Evans GL, de Souza Santos R, Grant AP, White TA, Monroe DG, Singh RJ, Casacalang-Verzosa G, Miller JD, Clegg DJ, LeBrasseur NK, et al. 2017b. 17α-estradiol alleviates Age-related metabolic and inflammatory dysfunction in male mice without inducing feminization. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 72:3–15. DOI: https://doi.org/10.1093/gerona/glx309

Strong R, Miller RA, Antebi A, Astle CM, Bogue M, Denzel MS, Fernandez E, Flurkey K, Hamilton KL, Lamming DW, Javors MA, de Magalhães JP, Martinez PA, McCord JM, Miller BF, Müller M, Nelson JF, Ndukom J,
Rainger GE, Richardson A, et al. 2016. Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a NrF2-inducer. Aging Cell 15:872–884. DOI: 10.1111/agec.12496. PMID: 27312325

Stubbins RE, Holcomb VB, Hong J, Núñez NP. 2012. Estrogen modulates abdominal adiposity and protects female mice from obesity and impaired glucose tolerance. European Journal of Nutrition 51:861–870. DOI: 10.1007/s00394-011-0266-4. PMID: 22042055

Szefer J, Kruzewski WJ, Sobczak E. 2015. Factors influencing the eicosanoids synthesis in vivo. BioMed Research International 2015:690692. DOI: 10.1155/2015/690692. PMID: 25861641

Tao R, Wang C, Stôhr O, Qiu W, Hu Y, Miao J, Dong XC, Leng S, Stefater M, Stylopoulos N, Lin L, Copps KD, White MF. 2018. Inactivating hepatic follistatin alleviates hyperglycemia. Nature Medicine 24:1058–1069. DOI: 10.1038/s41591-018-0048-0. PMID: 29867232

Taylor SE, Martin-Hirsch PL, Martin FL. 2010. Oestrogen receptor splice variants in the pathogenesis of disease. Cancer Letters 288:133–148. DOI: 10.1016/j.canlet.2009.06.017. PMID: 19608332

Tchkonia T, Morbeck DE, Von Zglinski T, Van Deursen J, Lustgarten J, Scrabble H, Khosla S, Jensen MD, Kirkland JL. 2010. Fat tissue, aging, and cellular senescence. Aging Cell 9:667–684. DOI: 10.1111/j.1474-9726.2010.00608.x. PMID: 20701600

Timper K, Brüning JC. 2017. Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity. Disease Models & Mechanisms 10:679–689. DOI: 10.1242/dmm.026609. PMID: 28592656

Toran-Allerand CD, Guan X, MacLusky NJ, Horvath TL, Diano S, Singh M, Connolly ES, Nethrapalli IS, Tinnikov AA. 2002. ER-X: a novel, plasma membrane-associated, putative estrogen receptor that is regulated during development and after ischemic brain injury. The Journal of Neuroscience 22:8391–8401. DOI: 10.1523/JNEUROSCI.22-19-08391.2002. PMID: 12351713

Toran-Allerand CD. 2005. Estrogen and the brain: beyond ER-alpha, ER-beta, and 17β-estradiol. Annals of the New York Academy of Sciences 1052:136–144. DOI: 10.1196/annals.1347.009. PMID: 16024756

Toran-Allerand CD, Tinnikov AA, Singh RJ, Nethrapalli IS. 2005. 17α-estradiol: a brain-active estrogen? Endocrinology 146:3843–3850. DOI: 10.1210/endo.2004-1616. PMID: 15947006

Torre D, Lolli F, Ciana P, Maggi A. 2017. Sexual dimorphism and estrogen action in mouse liver. Advances in Experimental Medicine and Biology 1043:141–151. DOI: 10.1007/978-3-319-70178-3_8. PMID: 29224094

Tyshkovskiy A, Bozyakut P, Borodinova AA, Gerashchenko MV, Ables GP, Garratt M, Khaitovich P, Clish CB, Miller RA, Gladyshev VN. 2019. Identification and application of gene expression signatures associated with lifespan extension. Cell Metabolism 30:573–593. DOI: 10.1016/j.cmet.2019.06.018. PMID: 31353263

Tzanetakou IP, Katsilambros NL, Benetos A, Mikhailidis DP, Perrea DN. 2012. ‘Is obesity linked to aging?’-adipose tissue and the role of telomeres. Ageing Research Reviews 11:220–229. DOI: 10.1016/j.arr.2011.12.003. PMID: 22186032

Veldhuis JD, Mielke KL, Cosma M, Soares-Welch C, Paulo R, Miles JM, Bowers CY. 2009. Aromatase and Salphea-reductase inhibition during an exogenous testosterone clamp unveils selective sex steroid modulation of somatostatin and growth hormone secretagogue actions in healthy older men. The Journal of Clinical Endocrinology & Metabolism 94:973–981. DOI: 10.1210/jc.2008-2108. PMID: 19088159

Vidal O, Lindberg M, Sävendahl L, Lubahn DB, Ritzen EM, Gustafsson JA, Ohlsson C. 1999. Disproportional body mass gain in female estrogen receptor-alpha-inactivated mice. The New York Academy of Sciences 8726.2010.00608.x

Villareal DT, Apovian CM, Kushner RF, Klein S, American Society for Nutrition, NAAASO, The Obesity Society. 2005. Obesity in older adults: technical review and position statement of the american society for nutrition and NAAASO, the obesity society. Obesity Research 13:1849–1863. DOI: 10.1038/oby.2005.228. PMID: 16339115

Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF. 2005. Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochemical and Biophysical Research Communications 336:1023–1027. DOI: 10.1016/j.bbrc.2005.08.226. PMID: 16165085

Waters DL, Ward AL, Villareal DT. 2013. Weight loss in obese adults 65years and older: a review of the controversy. Experimental Gerontology 48:1054–1061. DOI: 10.1016/j.exger.2013.02.005. PMID: 23403042

Wei L, Lai EC, Kao-Yang YH, Walker BR, MacDonald TM, Andrew R. 2019. Incidence of type 2 diabetes mellitus in men receiving steroid Salphea-reductase inhibitors: population based cohort study. BMJ 356:i1204. DOI: 10.1136/bmj.i1204. PMID: 30971393

Whitmer RA, Gundersen EP, Barrett-Connor E, Quesenberry CP, Yaffe K. 2005a. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 330:1360. DOI: 10.1136/bmj.38446.466238.e0. PMID: 15863436

Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. 2005b. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64:277–281. DOI: 10.1212/01.wnl.0000149519.47454.52. PMID: 15668425

Xiong Y, Lei QY, Zhao S, Guan KL. 2011. Regulation of glycolysis and gluconeogenesis by acetylation of PKM and PEPCK. Cold Spring Harbor Symposia on Quantitative Biology 285–289.
Xu Y, Nedungadi TP, Zhu L, Sobhani N, Irani BG, Davis KE, Zhang X, Zou F, Gent LM, Hahner LD, Khan SA, Elias CF, Elmquist JK, Clegg DJ. 2011. Distinct hypothalamic neurons mediate estrogenic effects on energy homeostasis and reproduction. Cell Metabolism 14:453–465. DOI: https://doi.org/10.1016/j.cmet.2011.08.009, PMID: 21982706

Yan H, Yang W, Zhou F, Li X, Pan Q, Shen Z, Han G, Newell-Fugate A, Tian Y, Majeti R, Liu W, Xu Y, Wu C, Allred K, Allred C, Sun Y, Guo S. 2019. Estrogen improves insulin sensitivity and suppresses gluconeogenesis via the transcription factor Foxo1. Diabetes 68:291–304. DOI: https://doi.org/10.2337/db18-0638, PMID: 30487265

Yang H, Youm YH, Vandamnagsar B, Rood J, Kumar KG, Butler AA, Dixo VD. 2009. Obesity accelerates thymic aging. Blood 114:3803–3812. DOI: https://doi.org/10.1182/blood-2009-03-213595, PMID: 19721009

Yang L, Fu WL, Zhu Y, Wang XG. 2020. Tbx4 suppresses lincRNA-p21-mediated hepatic apoptosis and fibrosis by inhibiting PI3K-AKT-NF-kB pathway. Gene 758:144946. DOI: https://doi.org/10.1016/j.gene.2020.144946, PMID: 32649978

Yu M, Benham A, Logan S, Brush RS, Mandal MN, Anderson RE, Agbaga MP. 2012. ELOVL4 protein preferentially elongates 20:5n3 to very long chain PUFAs over 20:4n6 and 22:6n3. Journal of Lipid Research 53:494–504. DOI: https://doi.org/10.1194/jlr.M021386, PMID: 22158834

Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nusbaum C, Myers RM, Brown M, Li W, Liu XS. 2008. Model-based analysis of ChIP-Seq (MACS). Genome Biology 9:R137. DOI: https://doi.org/10.1186/gb-2008-9-9-r137, PMID: 18798982

Zhang H, Liu Y, Wang L, Li Z, Zhang H, Wu J, Rahman N, Guo Y, Li D, Li N, Huhtaniemi I, Tsang SY, Gao GF, Li X. 2013. Differential effects of estrogen/androgen on the prevention of nonalcoholic fatty liver disease in the male rat. Journal of Lipid Research 54:345–357. DOI: https://doi.org/10.1111/jlr.028969, PMID: 23175777

Zhang J, Ren J, Wei J, Chong CC, Yang D, He Y, Chen GG, Lai PB. 2016. Alternative splicing of estrogen receptor alpha in hepatocellular carcinoma. BMC Cancer 16:926. DOI: https://doi.org/10.1186/s12885-016-2928-3, PMID: 27899088

Zhang X, Yang S, Chen J, Su Z. 2018. Unraveling the regulation of hepatic gluconeogenesis. Frontiers in Endocrinology 9:802. DOI: https://doi.org/10.3389/fendo.2018.00802, PMID: 30733709

Zhu L, Brown WC, Cai Q, Krust A, Chambron P, McGuinness OP, Stafford JM. 2013. Estrogen treatment after ovariectomy protects against fatty liver and may improve pathway-selective insulin resistance. Diabetes 62:424–434. DOI: https://doi.org/10.2337/db11-1718, PMID: 22966069

Zhu L, Martinez MN, Emfinger CH, Palmasino BT, Stafford JM. 2014. Estrogen signaling prevents diet-induced hepatic insulin resistance in male mice with obesity. American Journal of Physiology-Endocrinology and Metabolism 306:E1188–E1197. DOI: https://doi.org/10.1152/ajpendo.00579.2013, PMID: 24691030